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C H A P T E R 1 
GENERAL INTRODUCTION: 
The main steps involved in glucose oxidation comprise glycolysis to pyruva­
te and lactate (Embden-Meyerhof pathway), transport of pyruvate into the mito­
chondrion, oxidative decarboxylation of pyruvate to acetyl-CoA by the pyruva­
te dehydrogenase complex (PDHC) and the entrance of acetyl-CoA as the C2 
moeity to the tricarboxylic acid cycle, the final common pathway for the oxida­
tion of carbohydrate, fat and protein. In a series of reactions, COj and reducing 
equivalents are formed, the latter entering the respiratory chain where large 
amounts of high energy phosphate are generated in the process of oxidative 
phosphorylation. 
Due to rapid progress in the diagnosis of mitochondrial disorders, an increa­
sing number of diseases associated with biochemical defects in mitochondrial 
substrate transport, substrate utilization and in the respiratory chain have been 
found in recent years (13,27,43). As symptoms of muscular dysfunction such as 
severe hypotonia were frequently observed in these disorders, they were first 
called mitochondrial myopathies. In case of central nervous system involve­
ment, they have been called mitochondrial encephalomyopathies and with mul­
tisystem involvement mitochondrial cytopathies. 
Defects of respiratory chain enzymes have attracted most attention in this 
group of disorders. At the biochemical laboratory of the Pediatric Department 
of the university hospital of Nijmegen, studies of pyruvate metabolism (1,53) 
including PDHC measurement and enzymes of the respiratory chain (16) have 
been carried out for several years, and a considerable number of patients with 
mitochondrial encephalomyopathies have been described (43,47). 
Defects in the PDI 1С have been proposed as important causes of congenital 
lactic acidosis (38). A great degree of clinical heterogeneity comparable to that 
of respiratory chain deficiencies exists. Despite progress in the molecular field 
of DNA diagnosis, measurement of activity of PDHC in combination with 
immunochemical analysis remains the most important diagnostic tool in the 
detection of PDHC deficiencies. 
1.1. Pyruvate dehydrogenase complex: 
PDHC occupies a key position in intermediary metabolism: it catalyzes the 
oxidative decarboxylation of pyruvate to acetyl-CoA. It is one of the major 
enzyme systems involved in the control of energy metabolism. The components 
of PDHC catalyse consecutive steps in the overall reaction: 
Pyruvate + CoA-SH + NAD* > Acetyl-SCoA + NADH + H* + C 0 2 
3 
^CoA-SH 
О 
[5H3-C-S-UPSHJ 
СНз-С-СООН^ S 
E2? [ÜPISHU 
[UpSjl 
Figure 1: Reaction sequence in the pyruvate dehydrogenase complex: 
The reaction is catalysed bequentially by three componenls of the complex: pyruvate dehydro-
genase (E|), which has thiamine pyrophosphate (TPP) as an essential cofactor; dihydrohpoyl tran-
sacteylase (E2) with a covalemly attached hpoic acid cofactor (oxidi/ed form of hpoic acid: I-ipS2, 
reduced fonn. LipSH) and flavin adenine dinucleotide (FAD) containing dihydrohpoyl dehydroge-
nase (E-j) (NAD and NADH: nicotinamide adenine dinucleotide and its reduced form) 
PDHC is a multi-enzyme complex consisting of five subunits, pyruvate 
dehydrogenase (E,), dihydrohpoyl transacetylase (E2), dihydrohpoyl dehydro-
genase (Ез) and two specific regulatory enzymes, pyruvate dehydrogenase 
phosphatase and kinase. Some roles in the catalytic function and organization 
of the complex have been postulated for an additional protein, component X 
(9,20). It is a 53 kD protein which is slightly more mobile on SDS gel than the 
E3 component. It resembles E2 in that it bears a lipoyl group attached lo a lysine 
residue (19,32). This lipoyl residue is capable of being acetylated if pyruvate is 
present. 
PDHC is a macromolecule with a Mw of (7-8.5) xlO6 Dalton. It is associated 
with the inner mitochondrial membrane. It has a diameter of about 50 nm (50). 
In mammals, 60 copies of dihydrohpoyl transacetylase (E2) form the central, 
symmetrical core with an appearance of a pentagonal dodecahedron to which 
multiple copies of pyruvate dehydrogenase (E^ and dihydrohpoyl dehydrogen­
ase (E^) are bound by non-covalent bonds. The Ej a2ß2-tetramers appear to be 
located on the 30 edges and the E-, homodimers in the 12 faces of the pentago-
nal dodecahedron (35). 
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Figure 2 shows the subunit composition of PDHC in eukaryotes (50). 
The regulatory enzyme PDH phosphatase is loosely bound to the complex, 
whereas PDH kinase is endogenous to it. 
Besides PDHC, two other 2-oxo acid dehydrogenase complexes (2-oxo-
glutarate and branched chain 2-oxo-acid dehydrogenase complex) exist as mul-
tienzyme complexes occupying key positions in intermediary metabolism. They 
are also located within mitochondria and consist of three different catalytic 
enzymes. 2-oxo-glutarate-dehydrogenase complex is a potentially regulatory 
enzyme of the tricarboxylic acid cycle. Branched chain 2-oxo-acid dehydrogen­
ase complex catalyzes an irreversible step in the catabolism of branched chain 
amino acids. The molecular structures and the catalytic reactions of the three 
multienzyme complexes possess similar features. 
PDHC is involved in both bioenergetic and biosynthetic pathways, since 
acetyl-CoA can be further metabolized via the citric acid cycle (muscle, liver, 
brain) or utilized in the synthesis of fatty acids and sterols (adipose tissue, liver, 
mammary gland)(12). It controls the supply of C2 fragments derived from car­
bohydrates and amino acids to the mitochondria and their subsequent oxidative 
metabolism. 
The activity of PDHC is regulated mainly by a phosphorylation-dephospho-
rylation cycle but also by end product inhibition by acetyl CoA and NADH. 
Various factors can modulate the phosphatase-kinase system (Figure 3). 
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Figure 3: Covalent modification of pyruvate dehydrogenase and its control by various substances. 
Decarboxylation of pyruvate, catalyzed by the E, component, is the rate 
limiting step in the overall activity of PDHC. Phosphorylation of pyruvate 
dehydrogenase (E|) («зЭг) i n the presence of PDH kinase and ATP occurs on 
three serine residues in its α subunit (25,26,33). Site 1 phosphorylation is prin­
cipally responsible for inactivation. Site 2 and 3 phosphorylations inhibit reac­
tivation by phosphatase. Multisite phosphorylation is seen as a mechanism 
locking the complex in an inactive form and as a safeguard against rapid reac­
tivation by phosphatase (33). It is known that the proportion of active complex 
in liver, muscle and heart is to be decreased by diabetes, starvation, sepsis and 
oxidation of fatty acids and ketone bodies and and it is increased by muscular 
effort (33,49,52). 
C-DNAvs encoding a- and ß-subunits of PDH (E,) have been cloned and 
sequenced (7,10,23). Recently the functional gene locus for the EL a subunit of 
human PDHC has been localized to the p22.1-22.2 region of the X-chromoso-
me (3) and the structure of the gene has been elucidated (29). This provides a 
number of possible explanations for the clinical and biochemical variability in 
patients with PDHC deficiency. The severity of PDH - E| α deficiency in affec­
ted females is to a large extent dependent on the X-chromosome inactivation 
pattern in the brain (28). The gene locus for Ε, β subunit has been found to be 
located on chromosome 3 (5). Therefore PDHC is a multisubunit enzyme 
where one subunit is autosomal, the other X-linked encoded. In the human 
population with PDHC deficiency located in the E, component, there may be 
two distinct populations of patients, one with an X-linked forni of the disease 
(defect in the α subunit) and one with an autosomal recessively inherited form 
(defect in the β subunit). So far , seven cases of mutations of the Ε, α gene 
have been reported in literature. Most of the cases were de novo deletions. 2-
and 3-base pairs (bp) (17), 4-bp (15), 7-bp (8), and 20-bp de novo deletions (6) 
have been found. In one patient, a 21-bp Ε, α insertion has been described (11). 
In a further patient, a single amino acid substitution (arg-his) has been reported 
(17). 
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1.2. Clinical aspects of pyruvate dehydrogenase deficiencies: 
Classification of PDHC defects based upon the biochemical lesions leads to 
five groups of disorders Ej, E2 and E, deficiencies, deficiency of component X 
as recently described (41 ), and defects of the regulation system of the multien-
zyme complex including phosphatase deficiency (22,31,36) 
The correlation between biochemical abnormality and clinical presentation is 
rather poor (39) A wide spectrum of clinical presentations can be found in pati­
ents with PDHC deficiency In general, the clinical presentation of PDHC defi­
ciency is dependent on the following aspects 
1 The type of the mutation 
2 The residual activity of the multienzyme complex 
3 The availability of alternative energy sources in different tissues 
4 In case of Ε, α deficiency, the X-chromosome inactivation patterns in 
heterozygous females 
Most patients with PDHC deficiency present with a defect of pyruvate dehy­
drogenase (PDH)(E|) (39) Their clinical findings are heterogeneous, and no 
correlation can be detected between residual enzyme activity and clinical sym­
ptoms The clinical presentation vanes even in patients with a defect at the 
same subunit level of EL (51) A common clinical finding in PDHC deficiency 
is a variable degree of neuromuscular involvement The predominance of CNS 
involvement can be explained by the dependency of the brain on a nearly nor­
mal PDHC activity Symptoms range from extreme floppiness to signs of spi­
nocerebellar involvement (intermittent ataxia in childhood), developmental 
delay, seizures, hypotonia and ataxia Signs of brain stem dysfunction include 
severe vomiting, respiratory failure and disturbances of ocular motility The cli­
nical course ranges from fatal lactic acidosis in the newborn to chronic neurolo­
gical dysfunction without severe lactic acidosis (cerebral lactic acidosis , 2) 
PDHC deficiency has been found in patients with leiglfs disease, Alpers4 
disease and in association with hypo- and dysmyelimsation (42) Congenital 
malformations have been observed in some patients with PDHC deficiency 
(39) 
Recently, Robinson et al (1990) desenbed two patients with a severe clini­
cal course of PDHC deficiency, both with severe psychomotor retardation, in 
whom an Ej (dihydrolipoyl transacetylase) and a component X deficiency have 
been found (41) Defects in the dephosphorylation of Ej α have also been 
described (22,31,36), but no specific clinical symptoms have been found in this 
type of defect 
E3 is a subunit not only of PDHC but also of the 2-oxo-glutarate and bran-
ched-chain 2-oxo-acid dehydrogenase complexes In patients with E3 deficiency 
in addition to lactic acidosis, excretion of a-ketoglutarate and other branched 
chain amino acids in urine can be found (18,30,37,40) 
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1.3. Clinical-chemical aspects: 
Lactic acidosis is a frequent finding in patients with mitochondrial defects 
including disorders of gluconeogenesis, PDHC and the respiratory chain 
Especially hypoglycemia points to a disturbance in the gluconeogenic pathway 
Lactacidemia can be missed by single measurements, and a correct sampling 
procedure is a prerequisite for valid results (24). In addition, determination of 
the lactate/pyruvate and ß-hydroxybutyrate/acetoacetate ratios can provide use-
ful information. 
The ß-hydroxybutyrate/acetoacetate ratio reflects the intramitochondrial 
redox state, whereas the lactate/pyruvate ratio reflects the equilibrium between 
their cytoplasmic production from glycolysis and their consumption by the dif-
ferent tissues. In some cases, it is possible to differentiate between deficiencies 
of PDHC and respiratory chain. In respiratory chain deficiency, these ratios can 
be elevated, because the pyruvate/lactate ratio is shifted towards lactate due to 
reduced NAD* generation within the mitochondrial respiratory chain. In PDHC 
deficiency, the L/P ratio can be low or normal, but we have also observed ele-
vated L/P ratio's m patients with PDHC deficiencies (unpublished results, see 
also patient A A. Chapter 4). 
During lactic acidosis, alanine in serum is often concomitantly elevated due 
to transamination of pyruvate. Some patients with cerebral lactic acidosis have 
been described (2), where high levels of lactate have been found only in CSl· 
Therefore, lactate measurements in CSF are recommended in all patients with 
neurologic symptoms and clinically suspected to be suffering from mitochon-
drial encephalomyopathy. 
Fasting and loading tests (with glucose and/or pyruvate) are only necessary 
in dubious cases and must be carried out cautiously since substrate loading can 
worsen symptoms in affected patients (46) 
New techniques allow in vivo estimation of metabolites in different tissues-
With 'H- and11? spectroscopy, lactate, ATP, ADP and creatine phosphate can 
be observed in vivo . With transmission near-mfrared spectroscopy, quantitati-
ve measurements of changes in the redox status of cerebral cytochrome oxidase 
have been carried out in newborn infants (14). These techniques will be a 
valuable aid for early noninvasive diagnosis of mitochondrial encephalomyopa-
thies including PDHC deficiency. 
1.4. En/yme measurement of PDHC: 
PDHC activity can be measured by estimation of NADH, acetyl-CoA or 
'
4C02 production There is still some controversy concerning the methodology 
of PDHC measurement (45). The measurement of ^COj formation has been 
used most commonly in the diagnosis of patients with mitochondrial disorders 
because of the sensitivity of this method. A disadvantage is the rate of sponta-
neous decarboxylation of pyruvate and the instability of |l-14C]-pyruvate. 
Procedures such as freeze drying and storage in vacuo at -20° С must be carried 
out, and the punty of the radiolabeled pyruvate has to be determined before use 
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and taken into consideration (54) The non-enzymic conversion of pyruvate to 
parapyruvate can be checked by high voltage electrophoresis of radioactive [1-
'
4C|-pyruvate So far, detailed description of the method using 'ЧЮ^ formation 
by fibroblasts (44) has formed the basis of measurement of PDHC in other tis­
sues 
Measurement of the activity of sujnmits of PDHC has been described for E, 
(48), E2 (4), E3 (34) and PDH phosphatase (36) 
1.5. Aim of the study: 
This thesis describes several important aspects of the diagnosis of PDHC 
deficiencies The first step of this study was the development of a reliable 
PDHC assay in muscle tissue for the diagnosis of mitochondnopathies In case 
of a PDHC deficiency, immunochemical detection of PDHC subumts has been 
performed using SDS-polyacrylamide gel electrophoresis and immunoblotting 
PDHC deficiency is a well-known cause of congenital lactic acidosis, and 
enzyme investigations are carried out already in the early neonatal period 
Therefore, investigation ot age dependency of PDHC is essential for correct 
interpretation of enzyme data in this period of life An animal study was perfor­
med to study the development of enzymes involved in the pyruvate oxidation 
pathway In addition pyruvate oxidation rates and PDHC activity were measu­
red in neonatal autopsy muscle samples 
To gain insight into tissue expression of mitochondrial defects, several tissu­
es were investigated in patients with mitochondnopathies, where an enzyme 
deficiency in muscle tissue had been found 
1.6. Outline of the study 
In the biochemical diagnostic procedure in patients suspected to suffer from 
a mitochondrial defect, measurements are earned out preferentially in muscle 
tissue Mitochondrial defects including PDHC are not expressed in fibroblasts 
in many cases (21) Since PDHC can undergo activation- inactivation due to 
multisite phosphorylation, defined conditions for measurement of PDHC in 
vitro are necessary Totally activated PDHC means the activity of the complete­
ly dephosphorylated enzyme complex The basal activity, more difficult to defi­
ne, probably indicating the phosphorylated status of PDHC, has been suggested 
to reflect the in vivo activity (52) It can hardly be estimated due to rapidly 
changing enzyme activity after biopsy Investigations have been earned out to 
set up a reliable method for measurement of a completely stimulated PDHC 
activity in muscle tissue (see Chapter 2) 
Animal studies have revealed that enzymes of the mitochondrial energy 
generating system in various tissues show a postnatal development No deve­
lopmental studies of PDHC have been earned out so far in skeletal muscle tis­
sue Since knowledge of age dependency of enzymes involved in the energy 
generating system is very important for the diagnosis of mitochondrial myopa-
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thies, especially in neonates, maturational aspects were studied in an animal 
model as well as in human neonates (see Chapter 3). Rat was chosen as the 
model since its neurological state at birth is comparable with that in humans. 
Further evaluation of PDHC defects needs a combination of enzyme activity 
studies with immunochemical analysis of the components of the multienzyme 
complex. Chapter 4 presents a patient with E, deficiency, where the defect has 
been characterized more precisely by immunochemical studies. 
In a survey of patients with a PDHC defect in muscle tissue, various other 
tissues were investigated in order to demonstrate tissue specificity of PDHC 
deficiency (see Chapter 5). 
The importance of examining PDHC activity even in patients where a defect 
in respiratory chain has already been established, is emphasized in Chapter 6. 
This is the first report on patients with combined defects of PDHC and the 
respiratory chain. 
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Abstract: 
A sensitive radiochemical method for the determination of the pyruvate 
dehydrogenase complex activity in skeletal muscle tissue based on the decar­
boxylation of [ l-^C] pyruvate to l4C02 is described. Measurements can be car­
ried out either in muscle homogenate or in 600 g supernatant, both obtainable 
from a small muscle biospy specimen (20 mg). In addition to NAD*1, TPP and 
coenzyme A in the incubation mixture, a preparation ot NADH: cytochrome с 
reductase (NADHCR) together with cytochrome с has a stimulating effect on 
the PDHC activity NADHCR constitutes an oxidation system tor NADH to 
prevent leedback inhibition. Addition of L-camitine also results in a stimulation 
of PDHC by trapping the produced acetyl-CoA as acelylcarnitine. Special care 
tor radioactive pyruvate with freeze drying and storage at -20° С under nitro­
gen, and dctcnmination of the purity during every PDHC assay is required. 
In the presented assay a Km value ot 0.21 mmol/l was found for pyruvate. 
The Lineweaver-Burk plot indicated non-linearity. With the described method, 
a totally Mg2* Ca2+ stimulated PDHC activity is measured. Addition of a puri­
fied specific PDH phosphatase did not yield a higher PDHC activity. Finally, 
comparison ot total PDHC activity with 11-I4C] pyruvate oxidation rates, both 
measured in the supernatant prepared from fresh muscle, shows an equimolar 
correlation, indicating that total PDHC activity is rale limiting in the assay for 
the pyruvate oxidation rate. Neonatal muscle exhibits five to ten times lower 
PDHC activities and pyruvate oxidation rates than controls (age > 3 years). 
Introduction: 
The pyruvate dehydrogenase complex (PDHC) occupies a key position in 
the intermediary metabolism: it catalyzes the oxidative decarboxylation of 
pyruvate to acetyl-CoA and is one of the major enzyme systems involved in the 
control of energy metabolism The activity of PDHC is regulated mainly by a 
phosphorylation - dephosphorylation cycle (1) but also by feedback inhibition 
by acetyl-CoA and NADH (2). 
Defects in the pyruvate dehydrogenase complex, mostly with an affection of 
the E, subumt of this complex (3), are important causes of disorders of the mit­
ochondrial energy generating system. Measurement of the PDHC activity in 
muscle tissue is of crucial importance in the diagnostic procedure of mitochon-
dnopathies. Muscle tissue is preferentially used for enzymatic examination in 
the diagnosis of mitochondrial cytopathies, because most enzyme defects are 
expressed in human skeletal muscle (4). A deficiency of PDHC in muscle tissue 
is not always expressed in fibroblasts (5,6) and if so, substantially high residual 
activities can be observed in fibroblasts (7,8,9). Muscle tissue is rich in mito­
chondria and muscle biopsy is, besides skin biopsy, a less severe intervention in 
patients compared to other organ biopsies. 
Most of the methods reported for measurement of PDHC in muscle tissue 
are derived from methods applied in platelets (10,11) or human fibroblasts (12) 
and are most commonly assays based on the l4C02 measurement from [1-MC] 
14 
pyruvate (5,10,11,13). A thoroughly explored assay for détermination of total 
PDHC activity in muscle tissue using [1-I4C] pyruvate as substrate is lacking so 
far, only estimation of pyruvate dehydrogenase ( E,) in human skeletal muscle 
has been reported (14). 
We describe here a sensitive radiochemical method based on the specific 
decarboxylation of [1-'4C] pyruvate to '^ CCb , which can be performed in small 
muscle samples (up to 20 mg, obtained by open or needle biopsy) Evidence is 
given for the measurement of a fully activated (dephosphorylated) enzyme 
complex. PDHC activities have been compared with [1-14C] pyruvate oxidation 
rates, both measured in the same muscle supernatant. 
Materials and methods: 
Reagents 
[1-ПС] pyruvate, sodium salt, was obtained from New England Nuclear, 
Dreieich, FRG (10 μΟ/μτηοΙ) Pyruvate, sodium salt, thuminepyrophosphate 
chloride (TPP), coenzyme A, tnhthium salt, L-camitine and cytochrome с were 
from Boehrmger Mannheim GmbH, Mannheim, FRG. 
Hyamine (hydroxide of hyamine*l()-x) was purchased from Packard Becker 
BV, Groningen, The Netherlands, and Beta-count from J.T. Baker Chemicals 
В V, Deventer, The Netherlands Other chemicals used were of analytical grade 
3-Fluoropyruvate, sodium salt, was from Aldnch-Europe, Bccrse, Belgium. 
Muscle tissue : 
M. quadriceps biopsies from 15 patients of both sexes ranging trom 3 to 46 
years, in which a mitochondrial defect had been excluded morphologically and 
biochemically were used as reference muscular tissues In 18 neonates having 
died within the first two months of life and in which a neuromuscular disorder 
had been excluded, m quadriceps was aulopsied after informed consent of the 
parents within one hour after death The muscle specimens were immediately 
homogenized. 
Methods: 
Only fresh muscle tissue, obtained by biopsy or autopsy, was investigated. 
SETH medium (250 mmol/1 sucrose, 2 mmol/1 EDTA, 10 mmol/1 Tns-HCl , 
pH 7.4, 50 U/ml heparin) was used as homogemzation buffer 10 % (w/v) 
homogenates and 600 g supernatants were prepared according to Fischer et al 
(15) Correlation studies of PDHC and pyruvate oxidation rates were carried 
out in each patient in the same postnuclear supernatant. 
ll-14C] pyruvate was freeze-dned immediately after dilution with 2 mmol/1 
pyruvate (5 цСі [1-"C] pyruvate, sodium salt, 10 mCi/mmol in 1 ml 2mmol/l 
pyruvate, sodium salt) and stored under nitrogen in sealed ampules at -20° С in 
small aliquots to minimize decomposition For each assay the purity of the 
radioactive pyruvate was determined by high voltage electrophoresis (16) and 
used into calculation of the radiospecific activity. Total pyruvate concentration 
was determined spectrophotometncally to get the precise substrate concentrati-
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on for each assay. NADH cytochrome с reductase (NADHCR) was prepared 
from rat heart mitochondria as described by Gohil et al (17). Pyruvate dehydro­
genase phosphatase, purified from pig heart muscle according to Siess and 
Wieland (18), was a generous gift from Prot Wieland and Dr I. 
Paetzkc/Mumch F.R G 
Phosphorylation of PDHC was done by preincubating the supernatant with 
0 5 mmol/1 ATP at 24 0 С for 1 hour. Residual ATP was removed by dialysis 
for 16 hours at 4 0 С according to Wicking et al. (19). 
Figure 1: 
Reaction principle of PDHC assay using [1-MC] pyruvate as substrate 
PDHC 
1 [ 1-I4C] Pyruvate +CoA + NAD+ > Acetyl-CoA + NADH + l 4 C0 2 
endogenous carnitine 
atetyltransfcrdse (CAT) 
II Acetyl-CoA + Carnitine > Acetyl-Carnitine + CoA 
NADHCR 
III NADH + H + + cytochrome с oxid. > NAD+ + cytochrome с red 
Reaction principle of PDHC assay using [1-"C| pyruvate as substrate is 
shown in figure 1. Incubation was carried out in 100 mmol/1 Tris butter contai­
ning 0.5 mmol/1 EDTA, 4 mmol/1 MgCl2, 2 mmol/1 CaCl2, 0 5 mmol/1 NAD\ 1 
mmol/1 TPP, 2 mmol/1 CoA, 0 08 mmol/1 cytochrome c, 5 mmol/1 L-camiline, 
pH 7.4 and 10 μΐ of a NADH . cytochrome с reductase preparation (17). 50 μΐ 
of homogenate (or supernatant) after three times freezing and thawing at -196 ° 
С and 25° С respectively were added to the mixture After preincubation tor 10 
mm at 37 0C incubation was started by addition of 50 μΐ [ 1-I4C] pyruvate solu­
tion ( 5mmol/l, 5цСі/т1 ). The final volume was 0.5 ml Blank values were 
obtained by replacing homogenate by SETH medium These blanks produced 
essentially the same amount of background counts as the test mixture m the 
presence of the specific inhibitor of PDHC fluoropyruvate Blank values were 
less than 0.05% of total counts added as [1-I4C] pyruvate. Incubation was per­
formed at 37 "C in 20 ml glass scintillation vials sealed by rubber stoppers. The 
vials contained a small plastic tube inside a plastic cylinder, the tube containing 
0.2 ml hyamine hydroxide (20). After 20 min incubation at 37 °C the reaction 
was stopped by addition of 0.2 ml of 3 mol/1 perchloric acid. The ' ΐ Ο ι libera­
ted was trapped in hyamine during a 60 min post-incubation at 0 0C. The amo­
unt of 14C02 was measured at 4 0C in 5 ml Beta-count in a Searl Mark III liquid 
scintillation counter Counting efficiency was about 88%. For measuring the 
total amount of radioactive pyruvate added, 50 μΐ of [1-14C1 pyruvate solution 
was added to 1 ml hyamine and measured in 5 ml Beta-Count (21). Protein was 
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determined according to Lowry et al (22) using bovine serum albumin as a 
standard. 
Calculation: 
The activity of PDHC (in nmoles. min"1, ml'1 homogenate) was calculated as 
follows: 
(dpm test - dpm blanc), nmoles pyruvate added .% purity of pyruvate . 1000 _ nmol. min ' . m l ' 
dpm of 50μ] radioactive pyruvate . t . 100 . ν homogenate 
t = incubation time in min and v= homogenate in μΐ 
Assay of П-'4С1 pyruvate oxidation rates: 
[1-,4C] pyruvate oxidation rates were determined as described by 
Bookelman et al. (20) in 600 g supematants in the presence of 20 mmol/1 creati­
ne and Ap5A (23). Pyruvate oxidation studies were carried out in the presence 
of 5 mmol/1 ADP and 10 mmol/1 malate. 
Results: 
In the PDHC assay "O^-production from [1-14C] pyruvate was proportional 
to the amount of the homogenate added up to 1.2 mg protein and to incubation 
time up to 60 min. The pH optimum of the activity was at 7.4. The activity 
appeared to be optimal after 3 times freezing/thawing the homogenate compa­
red with sonication (3x10 seconds at 0° С with a sonifier, Branson Sonic Power 
Company, model B-12, equipped with a micro-tip). Cofactors are required 
appropiate to the known properties of the PDH complex (10). In addition to 
TPP, NAD+ and CoA, also carnitine turned out to have a stimulating influence 
on the enzyme activity (Table 1). 
Table I Dependency of the PDHC assay on substrates and cofactors 
Incubation mixture residual activity (in %) 
all components 100 
omission of: 
TPP 
NAD* 
CoA 
Ca ! · 
Mg2* 
Mg2*, Ca2 ' 
L-camitine 
Cytochrome с 
NADHCR 
23 
6.8 
9.7 
62 
44 
59 
36 
51 
89 
17 
The addition ol cytochrome с and also to a less extent of NADHCR resulted 
in a stimulation of activity hurthermore addition of NADHCR gave a stabili­
zing effect, especially on the day to day reproducibility (22%, 2xSD; n= 9). 
Day to day reproducibility without NADHCR was around 35 % The within run 
variation was 2 4% (2xSD, n= 7) Table 1 summan/es the influence of various 
compounds. Optimal concentrations of 4mM tor Mg2+ and 2mM for Ca2* were 
found for a maximally stimulated en7yme activity (Table 2 a). There was no 
significant additional stimulatory effect after addition of exogenous PDH phos­
phatase as shown in Table 2 b. 
Table 2 a Stimulation of PDHC by exogenous Mg1* and Ca-* (homogenate used from two diffe­
rent muscle samples) 
Intubation mixture dpm/20 mm 
Mg 0mM(Ca*2mM) 1028 
Mg 2niM ' 4881 
Mg 4mM 7002 
Mg 6 т М Г)928 
Mg 8 т М 6729 
Mg ІОтМ б Ш 
Ca - 0 т М (Mg ' 4 т М ) 69()S 
Ca 2 т М 8SÌ6 
Ca 4 т М 7974 
Ca * 6 т М 7295 
Ca ІОтМ 6262 
Table 2 b.: Stimulation of PDHC (in mU/mg protein) by exogenous (purified pig heart) PDH 
phosphatase (three different experiments) 
PDHC 
(with 1 mM AI Ρ during 
preincubation and dialysis) 
PDHC phosphorylated + 
exogenous PDH phosphatase 
I 
4 80 
5 96 
II 
5 29 
6 58 
4 0 0 
6 70 
PDHC assay without pretreatment 5 % 6 01 7 00 
with 4 mM Mg , 2 mM Ca 
Table 3 presents the effect of various inhibitors in the PDHC assay. 
Fluoropyruvate turned out to inhibit PDHC activity in the present assay almost 
completely (24) Also arscmte (inhibitor of the E
r
subunit) and rotenone (inhi­
bitor of complex I of the respiratory chain) inhibited PDHC activity considerab­
ly. Inhibition induced by various reaction products is also shown in Table 3. 
In the presented assay a Lincweaver-Burk plot indicated non-linearity (Fig 
2). A Km value of 0.21mmol/l was found for pyruvate applying the calculated 
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Hill coefficent of 1.72 (V max= 0.35 mU). Table 4 summarizes PDHC activi­
ties in homogenates using different assays (values from literature) in compari­
son with our control values using the presented method. 
Table 3. Inhibition of PDHC by various components 
Incubation mixture residual activity ( in % ) 
complete assay 
+ fluoropyruvate 
+ arse π ite 
+ rotenone 
+ acetylCoA/CoA 10:1 (2mM)* 
+ NADH/NAD* 1 2 (2mM)* 
+ ATP/ADP5:1 (2mM)* 
' sum of concentrations of both compounds is 2mM 
Table 4. Values for total PDHC in human skeletal muscle tissue 
(homogenate) from literature and our control values (mU/mg protein) 
100 
0.8 
1 9 
3.9 
167 
4 0 
41.1 
mean ± SD or range 
Toshima 1984 
Matuda 1984 
Evans 1981 
Evans 1981 
Wexler 1988 
Kerr 1987 
4.6+0 89(3.4-6 18) 
0.35-0 63 
2 36-4.78 
3 06±1 17 
2 5411 26 
2 7 (0.9-6 7) 
present assay : 
Homogenate, prepared from fro/en muscle 
Homogenate, prepared from fresh muscle 
Supernatant (600xg), prepared from fresh muscle 
5 0 + 1 8 (2.7-82) n= 15 
6 5 + 2 4 (3.05-11 8) η = 25 
6 8+2.7(3.5-11.7) π =16 
In Figure 3 correlation (R value: 0.82 ) of PDHC activity and [1-'4C] pyruva­
te oxidation rates is shown, when both properties arc measured in 600 g super-
natants. The results indicate a 1:1 correlation between total PDHC activity and 
pyruvate oxidation rate under the applied conditions. Only with added NADH-
CR the constant correlation between PDHC and pyruvate oxidation rates was 
found. Figure 4 demonstrates the same correlation in a group of neonates. 
Discussion: 
From the three main principles to measure PDHC activity, estimation of 
NADH or acetyl-CoA formation by spcctrophotometric assay or CO2 formation 
with radiochemical methods, the latter assay is the most sensitive one (26). The 
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Michaelis-Menten Plot 
of PDHC 
2a 
1 0 2.0 
S - ( pyruvate ] mM 
Lineweaver-Burk 
for PDHC 
2 0 -
1 0 -
0 -
• 
• 
• 
- · 
Plot 
• 
2b 
0 10 20 
1/S t pyruvate ]-l mM-1 
Figure 2: a. Michaelis Menten plot and b. Lineweaver-Burk (LB) plot for the dependency of 
PDHC activity on pyruvate concentration. 
assay using [1-14C] pyruvate as substrate has well described methodological 
disadvantages and care must be taken to diminish these problems as much as 
possible (26). First non-enzymic conversion of pyruvate to parapyruvate has to 
be taken into account (26). Even with improved storage conditions of [1-14C] 
pyruvate, a non-enzymatic conversion of pyruvate to 2,4-dihydroxy- 2-methyl-
Pyruvate oxidation / PDHC 
Controls (n=14) 
£ 400-
Pyruvate oxidation/PDHC 
Neonates (n=18) 
За 
200 300 400 500 600 700 800 
1-14C Pyr.+mal /nmol/h/mg prot 3b 
0 100 200 
1-14C Руг + mal./nmol/K/mg prot 
Figure 3: Correlation of total PDHC activity with [1- C] pyruvate oxidation with malate and ADP 
in 600 g supematants of control human muscle, a: controls, age 346 yr, η =14 and b: neonates , 
age < 2 months, n=18. 
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glutanc acid (parapyruvale) takes place (16) Over a penod of 4-8 weeks, even 
under special storage conditions (16) we observed a non-enzymic conversion 
up to 15 % of [1-MC] pyruvate to parapyruvate, the extent being batch depen­
dent. This amount of impurity has to be determined (16) for every ampule and 
correction tor it has to be done in calculating the specific activity. Secondly 
spontaneous decarboxylation of pyruvate can disturb the enzyme assay due to 
high blanc values (28). Dithiothreitol and Triton X 100, commonly used in 
PDHC assays, have to be omitted because of their induction of spontaneous 
decarboxylation (28) We have chosen for omission of sample as optimal blanc 
incubation mixture with replacement by buffer and obtained identical blanc 
values as in the presence of the strong PDHC inhibitor fluoropyruvate in the 
reaction assay (29) This procedure is also tissue sparing 
It is well known, that PDHC is inhibited by NADH and acetyl-CoA. 
Therefore in addition to the cofactors required by PDHC such as NAD+, TPP 
and CoA, an oxidation system is needed for oxidation of NADH and a regene­
ration system tor CoA tormed trom acetyl-CoA In the development of our 
enzyme assay it has turned out that addition of cytochrome с has a clear stimu­
latory effect on the PDHC activity Because cytochrome с leaks probably out of 
the mitochondrion after disruption ot the mitochondrial membrane by the free­
zing/thawing procedure, addition of cytochrome с restitutes the oxidative capa­
city of the respiratory chain The strong inhibition of PDHC by rotenone indica­
tes the necessity ot an active respiratory chain within the assay. It is important 
to notice that in patients with deficiencies of the respiratory chain a diminished 
oxidation of NADH could result in product inhibition of the PDH complex 
Addition ot an exogenous NADHCR preparation in the PDHC assay (17) to eli­
minate a possible detect in the respiratory chain is necessary in the diagnosis of 
patients with mitochondrial myopathies because a defect in the respiratory 
chain could otherwise simulale a defect in the PDHC From diagnostic view it 
is important to distinguish patients with a defective respiratory chain from pati­
ents with both a defect in PDHC and in the respiratory chain which have also 
been reported (30). The addition of a respiratory chain preparation to our con­
trol samples with an intact respiratory system results only in a moderate stimu­
lation of about 10 % (table 1) compared with PDHC values measured without 
addition and it has a considerable stabilizing effect on the en/yme assay (17) 
(see results). The cause of this stabilization is unknown Addition of carnitine 
to the assay regenerates acetyl-CoA to CoA with help of the endogenous carnit­
ine acetyl transferase (Fig 1.) The intactness of the regulatory system of PDHC 
in our enzyme assay appears from the observed inhibitions obtained by high 
ratios of acetyl-CoA/CoA, NADH/NAD+ and ATP/ADP (Table 3). 
A nonlinear Lincweaver-Burk plot indicates cooperalivily (Fig 2) Since η 
value m the Hill equation is 1 72, PDHC in human muscle tissue likely has two 
active sites (31,32), which stimulate each other at substrate binding In accor­
dance to other reports, we found an optimal PDHC activity in the presence of 
magnesium (4 mM) and calcium (2mM) This can be explained by stimulation 
of endogenous PDH phosphatase and dephosphorylation of the complex by 
both cations (33). Addition of a purified exogenous PDH phosphatase did not 
result in an increase of the complex activity in the presence of Mg2+ and Ca2+, 
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indicating that PDHC is completely activated under our assay conditions. 
Totally activated PDHC activities were compared with pyruvate oxidation 
rates both measured in 6(X) g supernatant of the same controls. [1-'4C] pyruvate 
oxidation was measured in fresh supernatant with intact mitochondria "СОт 
production is then the result of decarboxylation of [ 1-'4C] pyruvate after uptake 
in mitochondria and complete oxidation by the mitochondria. PDHC however 
is assayed in the supernatant after destruction of the mitochondrial membranes 
by free/mg/thawing and after adding cofactors and other compounds. Both 
assays revealed an equimolar substrate flux of pyruvate (bigure 3). This obser­
ved 1:1 correlation of pyruvate oxidation rates under state 3 conditions (sub­
strates and ADP are present in saturating amounts) with PDHC activity indica­
tes, that PDHC is in its dephosphorylated state during the incubation of intact 
mitochondria with [1-I4C] pyruvate under the described conditions and that 
PDHC activity is likely the rate limiting step in the pyruvate oxidation rale 
Comparing the en/yme activity of the neonates with the control group, age 
dependency of PDHC activity and pyruvate oxidation can be seen (25). 
Neonatal values of pyruvate oxidation and PDHC are 5-10 times lower than in 
controls (older than 3 years )(25) 
Although several reports in literature advocate the measurement of a basal 
PDHC activity, the definition of such an activity is rather obscure 
Measurement of PDHC without stimulation of the en/yme complex with the 
divalent cations results in a so called in vitro " basal activity". It has not been 
proven, whether this measurement is in accordance with the phosphorylation 
status of the en/yme complex. Furthermore meticulous attention is necessary in 
the tissue preparation to maintain an actual (in vivo) phosphorylation status of 
the en/yme complex. Freeze clamping of muscle tissue and inhibition of the 
regulation system of PDHC during tissue homogeni/ation and the pre- and 
incubation period are at least necessary. Such procedures are not practicable in 
the case of human muscle biopsies 
In summary, our assay of total PDHC activity provides higher en/yme 
activities than those so far reported in literature (Table 4) The method is appli­
cable even in small muscle specimen (20 mg) and has proven its value in the 
diagnosis ol mitochondrial myopathies of several patients with PDHC deficien­
cy (7,9). The assay has its special value in cases of combined PDHC and respi­
ratory chain deficiencies (30), since product inhibition is prohibited by addition 
of NADHCR as an oxidation system. Measurement of both, total PDHC activi­
ty and pyruvate oxidation rates in intact mitochondria have shown an equimolar 
correlation. 
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C H A P T E R 3 
DEVELOPMENTAL ASPECTS OF THE PYRUVATE 
OXIDATION PATHWAY 
3.1. 
POSTNATAL DEVELOPMENT OF PYRUVATE 
OXIDATION IN M. QUADRICEPS OF THE RAT 
Speri W., Sengers R.C.A., Trijbels J.M.F., Ruitenbeek W., 'De Graaf R., 
Ter Laak H., Van Lith Th., Kerkhoff C, Janssen A. 
1 2 1 
Departments of Paediatrics, Medical Statistics and Neurology, University of 
Nijmegen, The Netherlands 
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Abstract: 
In order to evaluate age dependency of enzymes involved in the energy 
generating system skeletal muscle specimens from rats of different ages were 
investigated for several mitochondrial enzymes. [1-I4C] pyruvate (± ADP) oxi­
dation rates and pyruvate dehydrogenase complex (PDHC) activity increased 
significantly from low early values in the neonatal period to nearly adult values 
at the end of the suckling period. Other enzymes ot the pyruvate oxidation 
route such as citrate synthase and cytochrome с oxidase showed similar pat­
terns of development Immunoblot studies of PDHC detected a clear increase in 
the intensity of the bands of the α subunit of E, (pyruvate dehydrogenase) and 
Ej (dihydrolipoyl transacetylase) within the first three weeks of lite The ratio 
between the individual PDHC proteins indicated that Ε,α , the regulatory subu­
nit of the multienzyme complex, is the most rapidly increasing protein with 
age. 
Introduction: 
Postnatal development of the mitochondrial energy generating system in the 
tissues of the newborn mammal is of crucial importance for adaptation to 
extrauterine life Various studies mainly in the rat have shown a postnatal 
increase of the oxidative capacity up to the weaning period (1-8) One key 
regulatory enzyme ot this mitochondrial oxidative system is the pyruvate dehy­
drogenase complex (PDHC), the rate limiting enzyme of aerobic glucose meta­
bolism The complex consists ot three catalytic (E, pyruvate dehydrogenase, 
consisting ot multiple copies of L·, a and Ε, β subunits, both forming a tetra­
mere, E2. dihydrolipoyl transacetylase and E, lipoamide dehydrogenase ) and 
two regulatory enzymes (PDH kinase and PDH phosphatase), giving it a mole­
cular weight of approximately 7 χ IO6 dallons 
Although detailed investigations of the postnatal development of the pyruva­
te dehydrogenase complex (PDHC) in brain (1-3,9,10), liver (11-13) and small 
intestine (14) have been performed in animals no investigation of PDHC in 
neonatal skeletal muscle has yet been carried out. burthermore, little is known 
about the development ot the whole pyruvate oxidation pathway in muscle tis­
sue (15) The development of the anaerobic metabolism (16, 17) and fatty acid 
oxidation (15,18,19,20) in muscle tissue has received more attention 
The present paper reports the findings of measurements of pyruvate oxidati­
on rate and PDHC activity in the quadriceps muscle of the rat in vitro at various 
times during late fetal and early postnatal development. The data are supple­
mented by histochemical and immunochemical studies. 
Materials and Methods: 
Animals· 
Albino Wistar rats, fed ad libitum were used for all studies The litters ran­
ged in size from 10 and 15 animals The time of birth was recorded carefully. 
For the postnatal investigations, animals from 4 nests were killed by cervical 
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dislocation at 24 hours and 7, 14 , 23 and 51 days after birth and quadriceps 
muscle was taken for investigation In order to obtain sulficient muscle tissue 
for enzyme studies, the samples were pooled on the first day of life from both 
hindlimbs of three animals from the same nest and on day 7 in the same manner 
from two animals The investigations of two time points in fetal development, 
day 19 and 21, used 3 or 4 litters. The animals were delivered by caesarean sec­
tion, and tissue samples from all fetal rats (10-15) from one mother were poo­
led. In all cases the complete quadriceps muscle was excised rapidly and was­
hed in SBTH medium (250 mmol/1 sucrose, 2 mmol/l EDTA, 10 mmol/1 Tris-
HC1 (piI 7.4 at room temperature), 50 U/ml heparin) (0-4°). If present, residual 
fat and connective tissue were dissected. The preparation of the tissue homoge-
nates and postnuclear 600 g supernatants was earned out as described previous­
ly (21,22). 
Chemicals: [1-I4C] pyruvate, sodium salt, was obtained from New England 
Nuclear, Dreieich, FRG (10 μΟ/μτηοΙ) Pyruvate, sodium salt, and thiaminepy-
rophosphate chloride (TPP) were from Boehnnger Mannheim GmbH, 
Mannheim, FRG. Tris(hydroxymethyl)aminomethane was from Fluka A.G., 
Buchs, Switzerland. Hyamine ( hydroxide of hyamine*l()-x) was purchased 
from Packard Becker BV, Groningen, The Netherlands, and Beta-count from 
J.T. Baker Chemicals В V, The Netherlands. Other chemicals used were of ana­
lytical grade. 
Assay of oxidation rates and enzyme activities: 
[ Ι - ' ΐ ] pyruvate oxidation rates were determined as described by 
Bookelman et al (22) in 600 g supernatants (21). Pyruvate oxidation studies 
were carried out in the presence and absence of ADP to provide insight into the 
coupling of oxidative phosphorylation All measurements were performed in 
triplicate. Total PDHC activity was measured in duplicate in 600 g supernatant 
as described recently (23). 
NADH Qt oxidoreductase and succinate : cytochrome с oxidoreductase 
were measured according to Fischer et al. (24), cytochrome с oxidase according 
to Cooperstein and La/arow (25), citrate synthase according to Srere (26). 
Protein was determined according to Lowry et al. (27). 
Immunoblot studies: Sodium dodecyl sulphate-polyacrylamide gel electro­
phoresis (SDS-PAGE) and immunoblotting for detection of PDHC subunils 
were earned out as described recently (23). Immunoblots were scanned with a 
laser densitometer (Ultrascan XL, Phanmacial/LKB Uppsala, Sweden). 
Histochemical studies: Transverse (8 μιη) sections were prepared from fro­
zen rat quadriceps muscle Histochemical staining for cytochrome с oxidase 
was carried out using the method of Novikoff and Goldfischer (28). 
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Table 1 Statistical findings of pairwise Scheffc comparisons between days for pyruvate oxidation 
rates and enzyme activities. 
Comparison Pyruvate oxidation PDHC total COX CS 
of ages +ADP -ADP +ADP -ADP protein CS (protein) 
days (protein) (CS) 
Fetal 
19,21 
19,1 
21,1 
Postnatal 
1,7 
1,14 
1,23 
1,51 
7,14 
7,23 
7,51 
14,23 
14,51 
23,51 
-
-
-
-
-
*** 
** 
-
*** 
** 
*** 
+* 
_ 
(*) 
** 
** 
) 
к _ 
к _ 
0 01 <p<0.0.<); ** 
** 
** 
** 
** 
** 
** 
= 0.001 < 
Ρ 
* 
** 
** 
** 
** 
** 
<0.01; 
*** 
*** 
*** 
*** 
*** 
*** 
****
 =
p < 
*** 
** 
*** 
** 
* 
-
0.001. 
- = 0.10 < p; (*) = 0.05 < ρ < 0.10; ' 
Statistical analysis: The age dependency of oxidation rates, PDHC and other 
enzyme activities was studied by means of analysis of variance. Duplicate or 
triplicate measurements were averaged. One-way analysis of variance was used 
to examine the differences between the two fetal times and the first day after 
birth, followed by pairwisc comparisons according to the simultaneous method 
of Scheffé. Two-way analysis of variance (mixed model) was applied to exami-
ne differences between the five postnatal times (day 1 to day 51), likewise fol-
lowed by pairwise Scheffé comparisons. A p-value of < 0.05 was considered to 
be statistically significant and 0.05 < ρ < 0.1 nearly statistically significant. 
Results: 
Pyruvate oxidation: [1-I4C] pyruvate oxidation rates are shown in Figure 1, 
expressed both on protein (Figure 1A) and on citrate synthase as a mitochondri­
al marker enzyme (Figure 1B). The oxidation rates show a similar pattem with 
a peak in the perinatal period (especially when expressed on CS-basis), low 
values in the first two weeks of life, generally an increase towards the end of 
the suckling period and adult values at weaning (day 23). 
The ADP stimulation of pyruvate oxidation (= quotient of [1-I4C] pyruvate 
oxidation rate with and without ADP) increases with age from about 2.0 to 4.9. 
Table 1 gives details about statistical significance of differences. 
The overall hypothesis of equal means for fetal times day 19 and 21 and 
postnatal time day 1 has to be rejected for [1-14C] pyruvate oxidation - ADP 
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(CS) (p= 0.02) ; the mean for fetal day 19 is significantly lower than that for 
day 1 (for details see Table I). The overall hypothesis of equal means for the 
five postnatal limes has to be rejected with respect to oxidation rates (p < 
0.001). Generally, day 23 and day 51 show significantly higher means than 
days 1, 7 and 14 (for details see Table 1 ). 
Pyruvate oxidation 
(nmol/h/mg protein) 
1200 
1000 • 
800 
600-
400 
200 
(1-uC)Pyr*ADP 
-i 1 1 -
¿5 55 
Age (days) -3 -11 5 Fetal Birth 
Fig. la 
Figure 1: Pyruvate oxidation rates with and without ADP-stimulalion in rat skeletal muscle are 
shown with increasing age. Oxidation rates are expressed on protein (big. la) and citrate synthase 
(Fig lb). 
Pyruvate dehydrogenase complex: 
Total activated PDHC activity (PDHC tot), expressed on protein and citrate 
synthase, is shown in Figure 2. The developmental pattern for total PDHC 
activity is similar to that seen for pyruvate oxidation, with an increase in the 
third week of life. One-way analyses of variance comparing the three perinatal 
times yielded overall p-values greater than 0.10. The postnatal analyses of vari-
ance yielded an overall p-value < 0.001 for PDHC tot (expressed on protein and 
CS). Pairwise comparisons with respect to PDHC tot (Table 1) give significant-
ly higher means for day 23 and 51. 
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Respiratory chain enzymes: 
Cytochrome с oxidase and citrate synthase activities, expressed on protein, 
are presented in Figures 3 a and 3 b. They show comparable patterns of deve­
lopment with an increase of activity in the last third of the suckling period. No 
significant differences are found in the perinatal period (p > 0.10), but there is 
strong evidence for an increase with age in the postnatal period (overall hypo­
theses: ρ < 0.001). The results of the pairwise comparisons are presented in 
Table 1. 
Immunoblot studies: 
Immunoblots of PDHC were performed from 600 g supernatant of quadri­
ceps muscle on days 1, 7, 14, 23 and 51, all rats from one nest. The same subu-
nit pattern with bands relating to E2 (76-78 kDa) and E ^ (42-44 kDa) and Ε,β 
(34-37 kDa) can be observed at all ages investigated. A clear increase can be 
seen in Ejtt and Ε,β and E^  within the first 3 weeks of life (Figure 4 , Table 2). 
Densitrometric studies of the ratios between Ε,α, El β and E2 expressed on 
protein and CS both showed that Ε,α is the most rapidly increasing protein 
with age. Its contribution increases from 46% at day 1 to 76% at day 51 (Table 
2). 
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Figure 2. Total activated pyruvate dehydrogenase complex activity (PDIIC total) expressed on pro­
tein (Fig 2a) and citrate synthase (Fig 2b) is shown with increasing age. 
Histochemical studies: 
Histochemical staining of m. quadriceps of the rat for cytochrome с oxidase 
(COX) is presented in Figure 5 for various ages. The increase in staining activi­
ty seen in the histochemical sections is in good accordance with the biochemi­
cal data on the enzyme. Till day 14 no clear differentiation between the fiber 
types exists. 
Discussion: 
Oxidation rates of [1-I4C] pyruvate as well as the activity of the mitochondri­
al enzymes pyruvate dehydrogenase complex, citrate synthase and cytochrome 
с oxidase in rat skeletal muscle generally increased significantly in the last third 
of the suckling period, rising from early neonatal values to nearly adult values 
at weaning. Expressed on the marker enzyme citrate synthase, the oxidation 
rates showed an increase in the late fetal period and at the time of birth (Fig 1). 
This can be explained by a steeper increase in citrate synthase in the perinatal 
period than the pyruvate oxidation rate, both expressed on protein. 
Extensive investigations of pyruvate oxidation in muscle tissue have not pre­
viously been conducted. Our biochemical results measured in a 600 g superna­
tant of quadriceps muscle at various ages reflect the average enzyme activity of 
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a heterogeneous skeletal muscle with a mixed fiber type composition. To avoid 
variation between genetically different animals, all measurements of each deve­
lopmental line were carried out within one nest. 
Our investigations indicate an increase in pyruvate oxidation rates in intact 
mitochondria as well as enzymes of the pyruvate oxidation route as a cluster in 
the second and third weeks of life. The weaning time around day 21 serves as a 
marker point. All various mitochondrial enzyme activities show an increase 
with age. The individual enzyme activities show differences in their age deve­
lopment in a quantitative way (see Fig 2 and 3). 
In our immunochemical studies of PDIIC, the Ε,α subunit, where the phos­
phorylation site of regulation of the whole multienzyme complex is situated, 
increases among the different subunits of PDHC most rapidly with age (Fig 4, 
Table 2). The most plausible explanation is that in addition to mitochondrial 
proliferation induction of enzyme synthesis takes place and is responsible for 
the increase in enzyme activity in the postnatal period. 
Maturation of mammalian skeletal muscle during the pre- and postnatal peri­
od involves a highly complex sequence of events. Differentiation of myotubes 
in different rat muscles, including m. quadriceps, into mature myofibers is lar­
gely completed by about three weeks of age (15, 29). The polyneuronal inner­
vation changes to single motoneuronal innervation in the third week of life in 
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Figure 3: Cytochrome с oxidase (COX) (Fig 3a) and citrate synthase (CS) (Fig 3b) in rat muscle 
increases with age till weaning 
the rat. Locomotion and posture of the newborn animal have also changed 
towards a more adult pattern by this time (15). Our biochemical and immuno­
chemical data on enzyme development are in good accordance with this time 
course of fiber type differentiation, as demonstrated also by the histochemical 
stainings (Fig 5). Thus, the maturation of the enzymes of the oxidative metabo­
lism of mitochondria takes place parallel to the functional and morphological 
development of muscle tissue. 
Pyruvate dehydrogenase complex (PDHC), one of the key regulatory enzym­
es of mitochondrial energy metabolism, is supposed to be rate-limiting for 
pyruvate oxidation (30). The parallel course of PDHC activity and pyruvate 
oxidation in our study of age development supports this hypothesis. 
Studies from Glatz and Veerkamp ( 18) have also shown an increase with age 
for palmitate oxidation, especially in the period up to weaning. At weaning dra­
stic nutritional and hormonal changes occur in the animal, including a switch 
from a high-fat to a carbohydrate-rich diet. During the suckling period, the rat 
receives milk with a high fat content (31), and active ketone body formation in 
the liver permits a good substrate supply for the developing brain. In rat brain, a 
difference of one week is seen in the duration of developmental increase bet­
ween CS and PDHC (3, 32). This difference, which can be attributed to the 
high ketone body utilizing capacity of the brain in this period, was not evident 
in our study of muscle tissue. It can be concluded from the data on fat and car-
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Figure 1-3 To avoid variation between genetically different animals, measurements of age deve-
lopment of enzymes and oxidation rates were tamed out within one nest Symbols indicate animals 
from one nest The line drawn in Fig 1-4 links mean values of enzyme activities measured at each 
step ot age 
bohydrate oxidation in rat skeletal muscle that the animal is ready to utilize 
both main energy sources for the muscle, glucose and fatty acids at the time 
when locomotion begins. Thereafter, fatty acid oxidation capacity declines (4) 
in response to the dietary changes, and hpogenesis is induced by the increased 
insulin glucagon ratio (33). 
The postnatal development of the muscular system has to be seen m associa-
tion with the development of the central and peripheral nervous system. Studies 
oi the local cerebral blood flow and local glucose utilization in rat brain indica-
te a high rate of both parameters shortly before weaning, reflecting the energy 
and biosynthesis needs ot the developing rat brain (34,35). Developmental 
events m skeletal muscle are probably induced by central and peripheral ner-
vous stimulation (36) Denervation and reinnervation studies have suggested 
the relevance of the innervating neuron type lor pyruvate metabolism (36). The 
acquisition of neurologic competence may be linked to the development of the 
aerobic metabolism in brain tissue, which may in turn be limited by the deve-
lopmental increase in PDHC activity (1). The development of enzymes of the 
oxidative system in brain and muscle tissue runs fairly parallel. In brain tissue 
of the rat, PDHC (10) and respiratory chain enzymes showed a developmental 
pattern similar to that found in rat skeletal muscle in our study, reaching nearly 
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adult values at the end of the third week of life (1,3,5,9) 
Other tissues such as heart, liver and brown adipose tissue also exhibited an 
increase in respiratory enzymes up until weaning (6,13) In conclusion, enzym­
es of the oxidative system seem to rise as a cluster in the neonatal period in dif­
ferent organs of the rat 
Table 2 Densitrometnc scanning of immunoblot analysis of Figure 4 
AU/mm/ 
mg protein 
AU mm/ 
mUCS 
Day 1 (Lane 2) 
Total 
Ε,β 
Ε,α 
E, 
Day 7 (Lane 3) 
Total 
Ε,β 
Ε,α 
E, 
Da) 14 (lane 4) 
Total 
Ε,β 
Ε,α 
E, 
Day 23 (Lane S) 
Total 
Ε,β 
Ε,α 
E, 
Day 41 (Lane 6) 
Total 
Ε,β 
Ε,α 
E, 
522 
67 
241 
274 
614 
24 4 
360 
230 
1332 
35 
942 
355 
3061 
104 
2149 
808 
2309 
42 
1744 
524 
100 
13 
46 2 
52 5 
100 
40 
58 5 
37 5 
100 
26 
70 7 
26 7 
100 
34 
70 2 
26 4 
100 
18 
75 5 
22 7 
9 6 
01 
4 4 
50 
93 
0 4 
55 
35 
11 2 
0 3 
80 
30 
158 
0 5 
11 1 
4 2 
143 
0 3 
10 8 
33 
100 
10 
46 8 
52 2 
100 
4 3 
58 1 
37 6 
100 
27 
70 5 
26 8 
100 
32 
70 3 
26 5 
НЮ 
2 1 
75 5 
22 4 
Total=E|a + E|ß + E, 
AU = arbitrary unit 
En/yme clusters can be induced by hormonal action at particular times 
during development (37) Thyroxine (4,38,39) and cortisone are probably 
involved in the induction of the mitochondrial oxidative system (40) There are 
indications that they are also involved in myofibrillar proliferation (40,41) In 
addition, catecholamines and a high ATP content may possibly induce the 
maturation of the inner mitochondrial membrane (42) 
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Figure 4. Immunoblol analysis of PDHC in muscle supematants from rats at different ages (day 1-
51). 
Lane 1 : molecular weight standards stained with Ponceau S (marked with a pen). Lane 2; muscle 
supernatant from 1 day old rat (1.58 μ§ prot.. 85.9 μυ CS) Lane 3: Muscle supernatant from 7 day 
old rat (1.73 № prot..l 14.2 μυ CS) Lane 4: 14 day old rat (1.68 μg prot.. 199.0 μυ CS) Lane 5: 23 
day old rat (1.58 μg prot., 305.3 μυ CS) Lane 6: 51 day old rat (1.63 μg prot., 262.6 μυ CS) Lane 
7: purified bovine PDHC (0.02 μ$ prot.) and E, (0.5 μg prot.). 
In recent years an increasing number of patients with mitochondrial ence-
phalomyopathies has led to an upsurge of interest in the biochemical aspects of 
oxidative metabolism in muscle tissue (43). Because a significant proportion of 
these patients develop their clinical symptoms in the neonatal period, knowled­
ge of age-related features of oxidative metabolism in muscle tissue is of great 
importance for the interpretation of data on mitochondrial enzymes in muscle 
tissues investigated for diagnostic purposes. 
Although rat has a comparable neurologic competency at birth to that in man 
and both can be considered non-praecocial species (2), extrapolation from our 
animal study to man must be done with caution. Low oxidation rates and low 
enzyme activities can also be found in human newboms in the first few days of 
life (44). The age at which oxidative capacity reaches adult levels is much less 
clear however. Although there are some similarities in neurological maturity at 
birth between man, primates and the rat, there are great differences in fiber type 
differentiation and maturation of the central nervous system. In man, this deve­
lopment is much slower during the first decade of life (45). In primates, PDHC 
seems to be already in a well developed range in full-term newborn animals. 
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Only the premature newborn primate exhibits a low pyruvate dehydrogenase 
activity (46). These data correspond to PDHC values in newborn babies at a 
different stage of maturation (47). Obviously, the rat is a neurologically less 
mature species at birth and its developmental pattern, especially in the weaning 
period, cannot be compared with man. 
Our study demonstrates a clear increase in mitochondrial oxidative capacity 
in rat muscle up until weaning. There is indication that the increase of PDHC 
activity is caused by an augmented protein synthesis. Apart from a less or more 
14 51 
Figure 5: Histochemical staining for cytochrome с oxidase in the developing rat quadriceps 
muscle. Note the increasing activity from fetal day 19 (f 19) to day 51 after birth (numbers indicate 
age in days). Immature muscle fibers can still be seen at day 14. 
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dspecific biosynthesis of mitochondrial enzymes, induction of specific proteins 
seems to take place, for example of the Ε,α subunit of the PDHC There is 
some indication that the increase in PDHC is due to increased synthesis of Ε,α, 
the regulatory subunit of the multienzyme complex. The developmental pattern 
of mitochondrial enzymes of the energy generating system in muscle tissue of 
the rat is in accordance with the known differentiation pattern of muscle fibers 
and seems to be related to the biochemical and neurological maturation of the 
brain. 
References: 
1 Malloch GDA, Munday LA Olson MS, Clark JB Comparative development of the pyruvate 
dehydrogenase complex and citrate synthase in rat brain mitochondria Bloch J 1986. 238 
729-736 
2 Booth RFG, Patel ТВ, Clark JB The development of enzymes of energy metabolism in the 
brain of a precocial (guinea pig) and non precocial (rat) species J Neurochem 1980, 34 17-
3 Land JM, Booth RFG, Berger R Clark J Development of mitochondrial energy metabolism 
in rat brain Bloch J 1977 164 339 348 
4 Nemeth PM, Noms BJ, Solanki L, Kelly AM Metabolic specialization in fast and slow 
muscle fibers of the developing rat J Neurosci 1989, 9 2336 2343 
5 Leong SF, Clark JB Regional enzyme development in rat brain Enzymes of energy metabo­
lism Biochem J 1984,218 139-145 
6 Lang CA Respiratory enzymes in the heart and liver of the prenatal and postnatal rat 
Biochem J 1965,95 365-371 
7 Jakovcic S, Haddock J, Get/ GS, Rabinowitz M, Swift H Mitochondrial development in 
liver ot foetal and newborn rats Bioch J 1971, 121 341 347 
8 Hallman M, Maenpaa P, Hassmen I Levels of cytochromes in heart, liver, kidney and brain 
in the developing rat Expenentia 1972, 28/12 1408-1410 
9 Cremcr JF, Teal HM The activity of pyruvate dehydrogenase in rat brain during postnatal 
development FEBS Letters 1974, 39 17 20 
10 Butterworth RF, Giguere J-F Pyruvate dehydrogenase activity in regions of the brain during 
postnatal development J Neurochem 1984, 43 280 282 
11 Knowles SE, Ballard FJ Pyruvate dehydrogenase activity in rat liver during development 
Biol Neonate 1974, 24 41-48 
12 Hron WT, Mcnahan LA Age related changes in activities of hepatic phosphofructokmase, 
pyruvate kinase and pyruvate dehydrogenase in liver and adipose tissue of the swiss albino 
mouse En/yme 1983, 30 83 88 
13 Bailey К Hahn Ρ, Palaty V Pyruvate dehydrogenase activity in liver and brown fat of the 
developing rat Can J Biochem 1975, 54 534 538 
14 Schiller CM Pyruvate dehydrogenase activity in hamster small intestine during development 
BiochJ 1977, 164 693-697 
15 Zuurveld JGEM, Wirtz P, Loermans HMT, Veerkamp JH Postnatal growth and differentiati­
on in three hindlimb muscles of the rat Characterization with biochemical and enzyme histo-
chemical methods Cell Tissue Res 1985, 241 183-192 
16 Novak E, Drummond Gl, Skala J, Hahn Ρ Developmental changes in cyclic AMP, protein 
kinase, and Phosphorylase in liver, hean, and skeletal muscle of the rat Arch Bioch Biophys 
1972, 150 511-518 
17 Villa-Morru//! b, Locci-Cubeddu T, Bergamini E Developmental changes of glycogen 
enzymes in fast and slow muscles of the rat Growth 1979 43 73 79 
18 Glatz JFC, Veerkamp JH Postnatal development of palmitate oxidation and mitochondrial 
enzyme activities in rat cardiac and skeletal muscle Bioch Biophys Acta 1982, 711 327-335 
38 
19 Carroll JE, McGuire BS, Chancey VF, Harrison KB Aevi CoA dehydrogenase enzymes 
during early postnatal development in the rat Biol Neonate 1989, 55 185 190 
20 Carroll JE, Shumate JB, Villadiego A, Choksi RM Morse DP Skeletal muscle fatty acid oxi­
dation during early postnatal development in the rat Biol Neonate 1983, 43 191-197 
21 Fischer JC, Ruitenbeek W, Stadhouders AM, Trijbels JMF, Sengers RCA, Janssen AJM, 
Veerkamp JH Investigation of mitochondrial metabolism in small human skeletal muscle 
biopsy specimens Improvement of preparation procedure Clin Chim Acta 1985, 145 89-
100 
22 Bookelman H, Trijbels JMF, Sengers RCA, Janssen AJM, Veerkamp JH, Stadhouders AM 
Pyruvate oxidation in rat and human skeletal muscle mitochondria Biochcm Med 1978, 20 
395 403 
23 Speri W, Ruitenbeek W, Kerkhof CMC, Sengers RCA, Injbels JMF, Guggenbichler JP, 
Janssen AJM , Bakkeren JAJM Deficiency of the a and β subunits of pyruvate dehydrogen­
ase in a patient with lactic acidosis and unexpected sudden death Eur J Pediatr 1990, 149 
487-492 
24 Fischer JC, Ruitenbeek W, Cabreéis FJM, Janssen AJM, Renier WO, Sengers RCA, 
Stadhouders AM, Ter Laak HJ, Trijbels JMF, Veerkamp JH A mitochondrial encephalomy 
elopathy the first case with an established defect at the level of coenzyme Q Eur J Pediatr 
1986,144 441-444 
25 Cooperstein SJ, Lazarow AS A microspectrophotometnc method for the determination of 
cytochrome oxidase J Biol Chem 1951,189 665 670 
26 Srere PA Citrate synthase, EC 4 13 7, citrate oxaloacetate lyase (Co A acetylatmg), in 
Lowenstein JM (ed) Methods in Enzymology London, Academic Prebs,1969, vol XIII, pp 
3 11 
27 Lowry OH, Rosebrough NJ, Farr AL, Randell RJ Protein measurement with the Folin phenol 
reagent J Biol Chem 1951, 193 265-275 
28 Novikoff AB, Goldfischer S Visualisation of peroxisomes (microbodies) and mitochondria 
with diaminoben/idine J Histochem Cytochem 1969, 17 675 680 
29 Curless RG, Nelson MB Developmental patterns of rat muscle histochemistry J Embryol 
bxp Morph 1976, 36 355-363 
30 Blass JP, Gibson GF Studies on the pathophysiology of pyruvate dehydrogenase deficiency, 
in Kark RAP, Rosenberg RN, Schut LI (eds) Advances m Neurology New York, Raven 
Press,1978,vol21,ppl81-194 
31 Dymsza HA, Czajka DM, Miller SA Influence of artificial diet on weight gain and body 
composition of the neonatal rat J Nutnt 1964, 84 100 106 
32 Land JM, Clark JB The changing pattern of brain mitochondrial substrate utilization during 
development Normal and pathological development of energy metabolism, in Hommes FA, 
Van Den Berg CJ (eds) London, Academic Press 1975, pp 155-167 
33 Pillay D, Bailey E Lipogenesis of the suckling-weaning transition in liver and brown adipose 
tissue of the rat Bioch Biophys Acta 1982, 713 663 669 
34 Nehhg A, Pereira de Vasconcelos A, Boyet S Quantitative autoradiographic measurement of 
local cerebral glucose utilization in freely moving rats during postnatal development J 
Neurosci 1988,8 2321-2333 
35 Nehhg A, Pereira de Vasconcelos A, Boyet S Postnatal changes in local cerebral blood flow 
measured by the quantitative autoradiographic [l4C| lodoantipynne technique in freely 
moving rats J Cerebral Blood Flow Metab 1989, 9 579 588 
36 Evans OB Muscle pyruvate oxidation following denervation and reinnervation Muscle 
Nerve 1983, 6 557 560 
37 Greengard О bnzymic differentiation in mammalian tissues Essays Bioch 1971, 7 159 205 
38 Mutvei A, Husman B, Andersson G, Nelson BD Thyroid hormone and not growth hormone 
is the principal regulator of mammalian mitochondrial biogenesis Acta Endocrinol 
1989,121 223-228 
39 Izquierdo JM, Luis AM, Cuezva JM Postnatal mitochondrial differentiation in rat liver J 
Biol Chem 1990, 265, 16, 9090-9097 
40 Kloosterboer HJ, Stoker-De Vnes SA Hulstaert CE, Hommes FA Quantitative analysis ot 
morphological changes in skeletal muscle ot the rat after honnone administration Biol 
39 
Neonate 1979; 35. 106-112. 
41. Butler-Browne GS, Barbet JP, Thomell LE: Myosin heavy and light chain expression during 
human skeletal muscle development and precocious muscle maturation induced by thyroid 
hormone. Anat Embryol 1990; 181. 513-522. 
42. Sutton R, Pollak JK: Hormone-initiated maturation of rat liver mitochondria after birth. 
Bloch J 1980; 186:361-367. 
43. Sengcrs RCA, Stadhouders AM, Tnjbels JMF: Mitochondrial myopathies. Clinical, morpho-
logical and biochemical aspects. Eur J Fed 1984; 141:192-207. 
44. Smeitink JAM, Sengers RCA.Tnjbels JMF, Ruitenbeek W, Daniels O, Stadhouders AM, 
Kock-Jansen MJH Fatal neonatal cardiomyopathy associated with cataract and mitochondri-
al myopathy. Eur J Pediatr 1989; 148 656-659. 
45. Burleigh IG: On the cellular regulation of growth and development in skeletal muscle. Biol 
Rev 1974,49 267-320. 
46. Robinson BH, Sherwood WG, Oei J: The development of pyruvate dehydrogenase in the 
subhuman primate Macaca mulatta. Biol Neonate 1977; 32:154- 157. 
47. Speri W, Sengers R, Ruitenbeek W, Tnjbels F, Boon H, (Collée L. Enzyme activities of the 
mitochondrial energy metabolism in skeletal muscle of preterm and full-term neonates J 
Neurol Sci 1990; 98 249 (abstr.) 
40 
3.2. 
ENZYME ACTIVITIES OF THE MITOCHONDRIAL 
ENERGY GENERATING SYSTEM IN SKELETAL 
MUSCLE TISSUE OF PRETERM AND FULLTERM 
NEONATES 
' W Sped, 2RCA Sengers,2 JMF Trijbels,2 W Ruitenbeek,3 WH Doesburg, 
' JAM Smeitink, " LAA Kollée, " JM Boon. 
Department of Paediatrics, University of Innsbruck, Austria 
Departments of Paediatrics and ^ Medical Statistics, University of Nijmegen, 
The Netherlands 
Ann Clin Biochem 1992: in print 
41 
Abstract: 
Quadriceps muscle specimens from autopsy of 28 neonates (gestational age 
25-42 weeks) were investigated to determine pyruvate and malate oxidation 
rates and several enzymes of the mitochondrial oxidative process. In general, 
the levels of all mitochondrial parameters measured, including carnitine levels, 
were lower in the neonates, having died within the first week of life, than those 
in the control group (age > 5 years). Pyruvate and malate oxidation rates (p< 
0.05), activities of pyruvate dehydrogenase complex (PDHC) (p< 0.10) and 
succinate: cytochrome с oxidoreductasc (p< 0.05) increased significantly with 
gestational age. Pyruvate oxidation rates (p< 0.05) as well as activités of citrate 
synthase (CS) (p< 0.05) and NADF^Qj oxidoreductasc (p< 0.05) were signifi-
cantly lower in the group of very preterm infants at an age of 1-7 days compa-
red with very preterm infants at an age between 3- 8 weeks. 
We conclude from our study that special reference values are necessary for a 
correct biochemical diagnosis of mitochondrial encephalomyopathics in the 
neonatal period. Differences between preterm and fullterm children of the same 
age (one week) indicate a maturational process in human muscle tissue during 
gestation. Comparison of two different age groups within the very preterm neo-
nates point to a postnatal maturation of the mitochondrial energy metabolism, 
at least in preterm neonates. 
Introduction: 
Mitochondrial encephalomyopathics constitute a heterogeneous group of 
disorders characterized primarily by functional and/or morphological abnorma-
lities of muscle mitochondria (1,2) and a varying degree of central nervous 
system involvement. Recent progress in diagnostic techniques has led to the 
detection of an increasing number of patients. A significant number of these 
patients develop the disorder in infancy, some immediately after birth with con-
genital lactic acidosis (3-6). 
Knowledge of the pre- and postnatal development of mitochondrial enzyme 
activities in human skeletal muscle tissue would be of great importance for the 
correct diagnosis of mitochondrial encephalomyopathics. Animal studies 
(7,8,9) and the scarce data available from human skeletal muscle tissue (10,11) 
indicate that enzyme activities of the mitochondrial energy generating system 
increase with age. 
Enzyme investigations are usually carried out first in biopsied quadriceps 
muscle (12,13,14). Tissue from other striated muscles biopsied, for example. 
during neonatal operations cannot be compared with quadriceps muscle since 
mitochondrial enzyme activities vary between muscle types ( 15). 
The present study carried out enzyme investigations in m. quadriceps muscle 
specimens obtained at autopsy from human neonates in order to evaluate the 
dependency of mitochondrial enzyme activities on age. 28 human neonates of 
different gestational ages were studied. Pyruvate and malate oxidation rales in 
intact mitochondria, total and free camitine concentration, and activities of 
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single enzymes such as pyruvate dehydrogenase complex (PDHC) and respira­
tory chain complexes were determined 
Materials and Methods 
Patients: 
Specimens of m quadriceps were obtained by autopsy from 28 newborn 
infants (19 male/9 temale), 23 of whom died at an age between one and seven 
days and 5 between 3 and 8 weeks Informed consent was obtained from the 
parents before autopsy. Specimens were taken within one hour of death. The 23 
children who died between one and seven days of life were classified into the 
following 3 groups group I very preterm (gestational age 27 - 29 weeks, n=8), 
group II preterm (30-36 weeks, n=7) and group III: full term neonates 
(37-42 weeks, n=8). Group IV consisted ot the 5 very preterm neonates 
(gestational age between 25 and 30 weeks) who died between 3 and 8 weeks 
after birth Patient data and major clinical complications are listed in Tables I 
and II. Histopathological and enzyme-histochemical investigations of the 
muscle autopsy specimens were carried out to exclude neuromuscular disease. 
Control muscle specimens were taken from patients (age > 5 years), who under­
went a diagnostic biopsy of m. quadriceps and in whom a mitochondrial defect 
had been biochemically excluded by normal oxidation rates as previously 
described (12) 
Tissue preparation: 
In 19 of the 28 cases, fresh muscle tissue was homogenized immediately 
after autopsy at 40C with a tissue chopper and Elveh|em potter according to 
Fischer et al.(13). Subsequently oxidation studies were carried out in 600 g 
supematants. Homogenate and supernatant were stored at - 70 ° С tor later 
investigations of enzyme activities In the lemaining 9 cases (group I n= 2, 
group II: n= 2, group III n= 3, group IV n= 2) autopsied muscle tissue was 
immediately fro/en in liquid nitrogen and stored at - 70oC until analysis 
Because of limited amounts of tissue not all enzyme measurements could be 
performed in all patients. Significant differences in fresh and fro/en muscle tis­
sue were found tor succinate · cytochrome с oxidoreductase (SCC) and cyto­
chrome с oxidase (COX) A correction factor was used for enzyme activities 
measured in frozen muscle tissue, so that they can be compared in statistical 
analysis with those measured in fresh tissue The distribution of fro/en tissue 
samples for COX measurement in the several groups was: group I n=2, group 
II n=2, group III· n= 3 and group IV n=2 SCC was measured in frozen tissue 
in the following distribution: group I. n=2, group II: n= 1, group III: n= 2 and 
group IV: n= 2). The correction factors were calculated from enzyme activities 
from control muscle tissue specimens (fresh/fro/en), where both fresh and fro­
zen muscle tissue from the same control patient was available. Control values 
for COX (homogenate): for fresh muscle tissue: mean:147±62 mU/mg protein, 
range: 68-289, n=15, frozen. m:l 13+42 mU/mg protein, range: 52-186, η = 15; 
correction factor for frozen tissue 1.33 ± 0 16 (95% confidence Intervall) 
range· 1.17-1.49. 
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Table I: Patient characteristics. Mean values ± standard deviation 
gestational 
age (weeks) 
age at death 
(days) 
sex (male/female) 
birth weight (g) 
Apgar score 
Imin 
Srnin 
group I 
(27-29 wk) 
n=8 
28.1+0.8 
2.3±1.6 
4/4 
1209±355 
44±1.6 
6.1 ±1.8 
group II 
(30-36wk) 
n=7 
33.4±2.2 
2.6±2 1 
5/2 
1827±565 
2.5±1.5 
5.8±2.0 
group III 
(37-42wk) 
n=8 
38.6±1.3 
3.6±1.5 
6/2 
2880±436 
6.8±2.3 
7.3±2.4 
group IV 
(25-30 wk) 
n=5 
27 1±2.1 
42.4±18.2 
4/1 
1094+325 
3.4±2.7 
6.3±1 7 
Table II. Clinical complications (number of patients are shown) 
complication 
Asphyxia 
Cerebral 
hemorrhage 
convulsion 
hydrocephalus 
Cardiovascular 
Cardiac defect 
Cardiomyopathy 
Patent ductus arteriosus 
Persist, fetal circulation 
Pulmonary hypertension 
Pulmonary 
Pneumothorax 
IRDS 
Lung bleeding 
Bronchopulmonal dysplasia 
Renal insufficiency 
Necrotising enterocolitis 
Congenital anomalies 
Chromosomal aberrations 
Group I 
(n=8) 
2 
4 
2 
1 
5 
4 
3 
4 
1 
3 
Group II 
(n=7) 
2 
1 
1 
1 
1 
2 
2 
1 
Group III 
(n=8) 
1 
1 
2 
2 
2 
1 
1 
1 
1 
Group IV 
(n=5) 
1 
4 
5 
1 
2 
1 
3 
2 
1 
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Control values for SCC (600 g superndtant) fresh m 50 7117 0 mU/mg 
protein, range 28 6-76 6, n= 9, frozen m 19 7± 10 6 mU/mg protein, range 
8 2-44 0, n= 9, correction tactor for frozen tissue 2 89 ± 0 70 (95% confidence 
intervdll) range 2 19-3 59 
Chemicals 
[1-I4C] pyruvate, sodium salt, and [U-'4C] malate were obtained from New 
England Nuclear, Dreieich, FRG (10 μΟ/μπιοΙ) Pyruvate, sodium salt, dnd 
thidminepyrophosphdte chloride (TPP) were from Boehnnger Mannheim 
GmbH, Mannheim, FRG Tris (Tris(hydroxymethyl)dminomelhdne) was from 
Fluka A G , Buchs, Switzerland Hyamine (hydroxide of hyamine* lO-x) was 
purchased from Packard Becker BV, Groningen, The Netherlands, and Beta-
count from J Τ Bdker Chemicdls BV, The Netherlands Other chemicals used 
were of analytical grade 
Table III Pyruvate and maiale oxidation rates in 600 g supernatant of neonatal skeletal muscle 
tissue (range and mean ± SD) 
Negn¡i|cs f i s i 
Oxidalion of Group 1 
25 29»к 
[1 С ] Pyruvate 9 4 57 5 
+maldte+ADP 32 9120 (6) 
018 1 89 
0 80+049(6) 
0 14 2 29 
094+0 73(6) 
[1 iCJ Pyruvate 107 707 
«amimc+ADP 518±27 8(4) 
0 4 1 2 6 
1 29±() 75 (4) 
0 1 8 2 9 6 
1 46+<) 99 (4) 
[ L ' C ] Malate 4 8 557 
+p>nivalc 1()8±2I6(6) 
ттаІоіше+ADP 0 19 1 71 
0 74+0 54(6) 
017 199 
0 86±0 68(6) 
Kendal l test tor rank corre 
wk ot life) 
Group II 
10 16wk 
29 5 78 7 
48 6+210(5) 
0 4 1 2 85 
1 10+0 94 (5) 
0 12 2 28 
1 20+0 81 (4) 
470 1062 
817:10 9(3) 
0 92 4 18 
2 26+171(1) 
1 15 114 
2 06+1 14(1) 
210-89 8 
46 8:25 7(5) 
047 191 
1 11±()57(5) 
0 35 154 
1 12+0 54(4) 
Group III 
1742*k 
49 0-182 5 
98 1+56 6(5) * 
059 2 29 
110-4)71(5) 
0 82-4 01 
2 74+118(5) 
69 1 179 1 
I04±5I(4)(*) 
(156 117 
I 6 5 ± l 10(4) 
116-5 51 
114+1 73(4) 
4012061 
104 4±65 5 (5) * 
0 11 2 27 
143+078(5)(*) 
1 01 4 55 
2 81±150(5)(*) 
lalion with duration o f pregnan 
( а б е З Ы ) 
Group IV 
25 10wk 
87 7 148 0 
112 4±316(1)+ 
215 1 36 
174+0 51(3) + 
151 1 89 
171±OI9(3) 
1188 1490 
Conlrols 
(>5 \ears) 
n=2() 
271 705 
473+117 
1 89 8 74 
1531173 
3 61 7 48 
5 52+099 
266 941 
I29 5;16 9(1)+504±I69 
I 16 1 22 
212+0 98(1) 
154 2 60 
2 07±0 51(3) 
361 1100 
816+19 8(1) 
097 148 
1 15+0 29(3) 
078 1 71 
121+048(1) 
189 960 
1681191 
2 84 8 24 
5 73+138 
320 996 
621+211 
181 101 
4 6912 41 
4 68 9 62 
7 18+1 28 
t y (group 1 I I and I I I ) * ι 
Units 
nmol/h 
mg prot 
nmol/h/ 
raU COX 
nmol/h/ 
mUCS 
nmol/h/ 
mg prol 
nmol/h/ 
mUCOX 
nmol/h/ 
m l ( S 
nmol/h/ 
mg prot 
nmol/h/ 
mU COX 
nmol/h/ 
m l CS 
) < 0 ( ) 5 stall 
stiLally significant (*) p< 0 10 marginally significant 
Wilcoxon s 2 sample test for comparison group I and IV + 
Number in brackets indicates number ot patients investigated 
ρ <005 
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Biochemical investigations: 
|1-I4C] pyruvate and [U-I4C] malate oxidation rates were determined in 600 
g supematants as dcscnbed by Bookelman et al. (12) but with the creatine/ 
creatine kinase system instead of the glucose/hexokinase system. Measurement 
of total PDHC activity was carried out as described (5). NADH: Qi oxidoreduc-
tase and succinate : cytochrome с oxidoreductase were measured according to 
Fischer et al. (16), cytochrome с oxidase (COX) according to Cooperstein and 
La/arow (17), citrate synthase (CS) according to Srcrc (18). Total and free car­
nitine concentration in muscle tissue was determined as described by Parvin 
and Pande (19). Protein was assayed according to Lowry et al. (20). 
Statistics: 
Comparison between group I and group IV was done by means of the 
Wilcoxon's two-sample test. Correlations between gestational age and enzyme 
activity were tested for using the Kendall test for rank correlation. P-values of 
less than or equal to 0.05 were considered statistically significant. 
Table IV : bn/yme activities ( mU/mg protein) and carnitine concentration (μιηοΙ/g wet weight) in 
neonatal skeletal muscle tissue (range and mean ± SD) 
Enzjmes 
PDHC(H) 
COX (H) 
CS(H) 
NADHQ|(S) 
SCC (S) 
camitme total (H) 
camnme free (H) 
Neonates ( l a w k of life) 
Group 1 
27-29»k 
15-8 3 
3 85+237(7) 
44 1-153 5 
83 2+401(7) 
401-962 
56 6119 5(7) 
066-646 
368±I95(6) 
3 81-27 5 
110±80(8) 
1 29-1 39 
13±0 04(5) 
079-1 12 
09±0I(5) 
Group 11 
30-36wk 
263 54 
4421101(6) 
704 178 6 
108 9+39 5(6) 
50 2-75 5 
6*419 1(6) 
183 998 
5 3212 85(6) 
710465 
18 4+14 8(6) 
0 76-2 13 
13+06(5) 
026-142 
0 8+05(5) 
Group 111 
3742wk 
347-114 
5 66+2 67 (7) (*) 
77 8-274 0 
129 0+718(8) 
513-1159 
68 4+22 2(8) 
178-8 6 
4 43+2 73(6) 
7 30-37 0 
18 6+91 (7)* 
1 28-1 96 
17+0 3(6) 
0 50 1 65 
10+04(6) 
Neonates (ape 3-8wk) 
Group IV 
25-3()wk 
084-11 1 
5 90+3 85(5) 
89 0-169 7 
1196+309(5) 
86 2-117 1 
99 4+119(5) + 
4 77-15 3 
113+45(4) + 
9 90-28 8 
20 817 9(4) 
1 23/1 83 
15+04(2) 
073/095 
0 8+02(2) 
Controls (>5 years) 
2 89-8 65 
6 70+240 
68 0-289 
147+62 
48 162 
913+32 0 
4 4-25 9 
I3 2±6 3 
28 6-766 
50 7117 0 
2 7 4 6 
36+05 
2.242 
3 2+1 1 
(n=22) 
(n=15) 
(n=32) 
(n=28) 
(n=9) 
(n=21) 
(n=21) 
Kendall tesi for rank correlation with duration of pregnancy (group 1,11 and III ) 
(*)p<0 10 
Wilcoxon's 2-sample test for comparison group I and IV + ρ < 0 05 
H muscle homogenate, S 600 g supernatant 
Number in brackets indícales number of patients investigated 
ρ <0 05, 
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Results: 
Pyruvate and malate oxidation rates in all neonates were significantly lower 
than those for the control group (age > 5 years) when expressed on protein con­
tent or marker enzyme activity. With duration of pregnancy an increase of the 
oxidation rates, when expressed on protein, can be found (Table III). However, 
when activity was expressed on marker enzymes citrate synthase (CS) and 
cytochrome с oxidase (COX), the differences were statistically not significant. 
This is because the activities of the latter enzymes increased nearly proportio­
nally with gestational age as well (Table IV). 
Respiratory chain complexes, especially succinate : cytochrome с oxidore­
ductase (SCC) (p< 0.05) and pyruvate dehydrogenase complex (PDHC) (p< 
0.10) showed a similar pattern of increasing values with a higher malurational 
status at term (Table IV). Comparison of two age groups (group I and IV) of 
very preterm neonates (gestational age between 25 and 30 week) revealed a sig­
nificant age dependency of pyruvate oxidation rate (p< 0.05) (Table III) as well 
as enzyme activities of the respiratory chain (Table IV). Citrate synthase (CS) 
(p< 0.05) and NADI-^Q, oxidoreductase (p< 0.05) activities were significantly 
lower in the group of very preterm infants, age 1-7 days (group I), compared 
with very preterm infants with death at an age between 3- 8 weeks (group IV). 
Carnitine content of muscle tissue in neonates was significantly lower than in 
children and adults (Table IV). The percentage of acylated carnitine increased 
with gestational age. 
Discussion: 
In this study investigation of human skeletal muscle tissue from autopsy of 
neonates with an age of one week of life revealed lower pyruvate and malate 
oxidation rates, lower respiratory chain enzyme activities and lower total carnit­
ine levels compared to the control group (age > 5 years; Table III and IV). 
Differences between preterm and fullterm children of the same age (I week) 
were mainly found for the oxidation rates (Table III) reflecting that the overall 
capacity of the mitochondrial oxidative system probably undergoes a maluratio­
nal process in human muscle tissue during gestation. Those differences were 
less pronounced in single enzyme activities and only a trend for an increase of 
enzyme activities with gestational age was seen for pyruvate dehydrogenase 
complex and succinate: cytochrome с oxidoreductase. Besides, comparison of 
oxidation rates and enzyme activities of two different age groups within the 
very preterm neonates (group I and group IV) revealed an age dependency of 
the oxidative mitochondrial system, pointing to a postnatal maturation, at least 
in preterm neonates. 
A low neonatal oxidative capacity is in agreement with the few data so far 
known for muscle tissue in humans (10,11) and animals (7,9). Moggio et al. 
(10) demonstrated an increase in COX activity in human fetal skeletal muscle 
with gestation. Robinson et al. (8) found a significantly lower PDHC activity in 
brain, kidney cortex, skeletal and cardiac muscle of preterm primates compared 
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with adult animals. Only in brain and kidney cortex a significant difference bet-
ween PDHC of preterm and term primates was found. Compared to the grade 
of prematurity ol the primates in Robinson's study our patients of the very pre-
term group are more premature Our data from human skeletal muscle are the-
refore not in contrast to the results of Robinson's primate study Recently a 
clear prenatal increase in activity and protein content was shown for mitochon-
drial creatine kinase of human skeletal muscle (21 ) In another study on the age 
dependency of various enzymes involved in the energy producing system in rat 
skeletal muscle tissue, we found an increase in the mitochondrial en/ymes up to 
the weaning period (9). Differentiation of the enzymes for the mitochondrial 
oxidative system has been shown in man as well as in animals not only for 
muscle but also for other tissues such as brain, liver and kidney (22.23,24,25). 
The results ol the present study indicate that age matched reference values 
are required for adequate diagnosis of mitochondrial encephalomyopathies. 
Patients with mitochondrial defects may present first symptoms in the neonatal 
period (3-6), and en/yme deficiencies have to be discriminated from the low 
control values of this period Two recent publications stress the possibility of a 
mitochondrial defect in association with neonatal respiratory distress syndrome 
(RDS). Both patients suffered from a COX deficiency (26, 27) Probably more 
patients suffer from classical neonatal disorders such as RDS but not all have 
been investigated for mitochondrial defects. 
In addition to diagnostic purposes our data contribute to the understanding of 
neuromuscular development Energy production from pyruvate is quite low in 
the newborn muscle tissue So far investigations ot human neonatal energy 
metabolism have predominantly been carried out by biophysical methods(direct 
and indirect calonmetry (28), thermodynamic model (29)) and only scarce data 
are available on enzymatic level 
The low carnitine levels found in neonatal skeletal muscle in premature 
babies are in accordance with low serum carnitine levels found in this period ot 
age (30). Also other investigators have lound low levels of carnitine in muscle 
tissue measured in autopsy samples of neonates and found also a positive corre-
lation with gestational age (30,31). 
The development ol the central and peripheral nervous systems and the ske-
letal muscle has to be considered in close association with each other (32) and 
innervation plays an important role in muscle differentiation (7,33) Enzymes 
of the pyruvate oxidation route in neonatal brain are also low compared to 
values in adults (34) and ketone body utilization in the newborn baby delivers 
the majority ot energy for brain metabolism. Dilferentialion ot muscle and 
brain tissue and development ot pyruvate oxidation in the rat is mainly comple-
ted at weaning, but the time course of neuromuscular development in man is 
much slower (35). The exact time, at which the pyruvate oxidation rate reaches 
adult values is still unknown. At an age of 3-8 weeks lower values are still 
found (Table III, group IV) The different oxidative capacity of skeletal muscle 
tissue at different maturational stages found in our study is in good agreement 
with differences in early neuromotor development found in preterm and term-
newbom infants (36, 37) 
Various lactors should be borne in mind when assessing the findings of this 
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study First, autopsy material has been investigated Histopathological and 
enzyme-histochcmical investigations showed morphological integrity of the 
muscle tissue Patients with muscular disease and major postmortem alterations 
could thus be excluded In our expenence, postmortem examination of muscle 
tissue taken within one hour after death yielded results comparable with those 
obtained with a fresh biopsy specimen (4,38) 
Secondly, most of the patients had been in intensive care Patients with sep­
sis were withdrawn from the study, since PDHC activity can be inhibited in 
sepsis (39,40) It can be seen from our patient data, that preterm babies suffered 
from more complications then the term ones (Table II) Furthermore the pre­
term infants had lower mean Apgar scores (Tabic I) Nearly all the infants had 
been ventilated artificially and a certain effect of tissue hypoxia with a possible 
influence on mitochondrial enzyme activities cannot be excluded The similari­
ty of the ratio's between the vanous enzyme activities in the several groups is 
in favour of a developmental process rather than an influence of, for example 
hypoxia, on an individual enzyme Also from other animal studies evidence is 
obtained that exposure to hypoxia does not result in decreased mitochondrial 
enzyme activities Eleander et al (41) studied metabolic adaptations to reduced 
muscle blood flow and concluded that intermittent hypoxia during contraction 
at reduced flow resulted in increased activities of mitochondrial enzymes 
Yoshing et al (42) studied acclimatization of rats to high altitude hypoxia and 
concluded that a shift occurred of the anaerobic glycolysis to aerobic metabo­
lism by the increase in the oxidative enzymes 
Therefore it is highly improbable that the significantly lower mitochondrial 
enzyme activities in the preterm infants as compared to adult controls are cau­
sed by tissue hypoxia Finally the differences in oxidation rates and enzyme 
activities found by comparison of two groups of very premature neonates of 
different age (group I and IV in Table III and IV) cannot be explained by more 
serious hypoxia or other complications, since both patient groups are very well 
comparable on clincal grounds (Table I and II) 
Knowledge of reference enzyme activities in the newborn is a fundamental 
requirement for the interpretation of values obtained from neonates suspected 
to suffer from a mitochondrial encephalomyopathy But they can only be acqui­
red from enzyme investigations of biopsy material, which for ethical ι casons is 
not possible Measurement of enzyme activities or oxidation rates in cultured 
fibroblasts is no alternative for an adequate diagnosis of mitochondrial myopa­
thies in the neonatal period since tissue specificity has been observed in mito­
chondrial defects and enzyme defects are often not expressed in cultured fibro­
blasts (14,41,44) 
So far in the literature no strong emphasis has been put on the careful inter­
pretation of mitochondrial enzyme data from neonates Our results from inve­
stigations of neonatal skeletal muscle obtained from autopsy provide some indi­
cation that there exists maturation and age dependency of mitochondrial enzy­
mes involved in the oxidative energy production in human skeletal muscle 
These results are important for the diagnosis of mitochondrial encephalomyo-
pathies in the neonatal period 
49 
References: 
1. DiMauro S, Bonilla E, Zeviani M Mitochondrial myopathies. Ann Neurol 1985. 17 521-
538 
2. Sengers RCA. Stadhouders AM. Tnjbels JMF. Mitochondrial myopathies. Clinical, morpho-
logical and biochemical aspects. Eur J Pediatr 1984, 141: 192-207 
3. Birch-Machm MA. Shepherd IM . Watmough NJ, Sherrat HSA. Bartlett K. Darley-Usmar 
VM, el al. Fatal lactic acidosis in infancy with a detect of complex 111 of the respiratory 
chain. Pediatr Res 1989; 25: 553-559 
4 Speri W, Ruitenbeek W, Sengers RCA, Stadhouders AM, Guggenbichler JP. Mitochondrial 
myopathy with lactic acidaemia. Fanconi-Dc loni-Debré syndrome and a disturbed succina-
te: cytochrome с oxidoreductase activity. Eur J Pediatr 1988, 147. 418-421 
5. Speri W. Ruitenbeek W, Kerkhof CMC, Sengers RCA. Tnjbels JMF. Guggenbichler JP. et 
al. Deficiency ol the a and β subunits of pyruvate dehydrogenase in a patient with lactic aci­
dosis and unexpected sudden death. Kur J Pediatr 1990; 149 487-492 
6. Wraith JE Diagnosis and management of mbom errors of metabolism . Arch Dis Child 1989. 
64 1410-1415 
7. Nemelh PM. Noms BJ , Solanki L. Kelly AM. Metabolic specialization in fast and slow 
muscle fibers of the developing rat. J Neurosci 1989, 9' 2336 - 2343 
8. Robinson BH, Sherwood WG. Oei J The development of pyruvate dehydrogenase in the sub­
human primate Macaca mulatta. Biol Neonate 1977: 32' 154- 157 
9. Speri W. Sengers RCA . Tnjbels JMF. Ruitenbeek W. De Graaf R. Ter Laak H. et al. 
Postnatal development of pyruvate oxidation in quadriceps muscle of the rat Biol Neonate 
1992:61: 188-200 
10. Moggio M. Bresolin N. Scarpani E. Adobbati L, Prelle A. Gallanti A. et al. Cytochrome с 
oxidase during human fetal development Int J Dev Neurosa 1989: 7: 5-14 
11 Smeitink JAM. Sengers RCA , Tnjbels JMF, Ruitenbeek W, Daniels O. Stadhouders AM. 
Fatal neonatal cardiomyopathy associated with cataract and mitochondrial myopathy. Eur J 
Pediatr 1989: 148.656-659 
12. Bookelman H. Tnjbels JMF. Sengers RCA, Janssen AJM, Veerkamp JH. Stadhouders AM. 
Pyruvate oxidation in rat and human skeletal muscle mitochondria Biochem Med 1978, 20 
395-403 
13 Fischer JC, Ruitenbeek W, Stadhouders AM, Tnjbels JMF, Sengers RCA, Janssen AJM, ct 
al Investigation of mitochondrial metabolism in small human skeletal muscle biopsy speci­
mens. Improvement ol preparation procedure. Clin Chun Acta 1985.145: 89-100 
14. Speri W. Ruitenbeek W. Tnjbels JMF. Korenke GC. Sengers RCA. Heterogeneous tissue 
expression of civyme defects in mitochondrial myopathies J Inhcr Mclab Dis 1990.13: 359-
362 
15 Veerkamp JH. The function of muscle mitochondria. In Busch HFM, Jennekens FGI. 
Schölte HR (Eds). Mitochondria and muscular disease. Mefar bv.. Bectster/waag. 1981, 29-
50 
16 Fischer JC. Ruitenbeek W. Gabrccls FJM. Janssen AJM, Renier WO. Sengers RCA. et al. A 
mitochondrial enccphalomyelopathy the First case with an established defect at the level of 
cocn7ymc Q. Eur J Pediatr 1986. 144: 441-444 
17. Cooperstein SJ. Lazarow AS. A microspectrophotomctric method for the determination of 
cytochrome oxidase. J Biol Chcm 1951, 189 665-670 
18. Srcrc PA. Citrate synthase. EC 4.1.3.7, curate oxaloacetate-lyase (Co A-acetylatmg). In: 
Löwenstein JM (Ed ) Methods in En/ymology London. Academic Press 1969; Vol. 13: 3-
11 
19 Parvin R, Pande SV: Microdetermination of (-) carnitine and carnitine acctyltransfcrase 
activity Anal Biochem 1977, 79 190-201 
20 Lowry OH, Rosebrough NJ, Farr AL, Randell RJ. Protein measurement with the Folin phenol 
reagent J Biol Chem 1951; 193: 265-275 
21. Smeitink JAM, Ruitenbeek W, v. Lith T, Sengers RCA, Tnjbels JMF, Kerkhof CMC. et al 
Maturation of mitochondrial and other isoenzymes of creatine kinase in skeletal muscle of 
preterm bom infants. Ann Clin Biochem 1992: in press 
50 
22. Parkas-Bargeton E, Dicbler MF, Rosenberg B, Wehrlé R. Histochemical changes of the deve-
loping human cerebral neocortex Studies on two enzymes of energy metabolism in three cor-
tical areas Neuropediatncs 1984,15· 82-91 
23. Greengard О Enzymic differentiation of human liver· comparison with the rat model. Pediat 
Res 1977, 11:669-676 
24. Hommes FA Energetic aspects of late fetal and neonatal metabolism In: Hommes FA, Van 
den Berg CJ ( Eds. ). Normal and pathological development of energy metabolism. London, 
Academic Press, 1975: 1-7 
25 Sengupta T, Dutla C, Dasgupta J, Sengupta D. Developmental changes of TCA cycle enzym­
es in human fetal brain. Indian. J Biochem Biophys 1988; 25: 404-407 
26 Hart Z, Chang CH. A newborn infant with respiratory distress and persistent stndulous brea­
thing. J Pediatr 1988, 113 150-155 
27. Takayanagi T, Inouc M, Tomimasu K, Shimomura C, Matsuzaka T, Tsuji Y, et a! Infantile 
cytochrome с oxidase deficiency with neonatal death. Pediatr Neurol 1989; 5:179-81 
28. Sauer PJJ, Pcarse RG, Dane HJ, Visser HKA The energy cost of growth estimated from 
simultaneous direct and indirect calonmetry in infants of less than 2500 g In. Visser HKA. 
(Ed ) Nutrition and metabolism of the fetus and infant The Hague, Martinus Ni]hoff 
Publishers 1979,93-107 
29. Simbruner G. Thermodynamic models for diagnostic purposes in the newborn and fetus. 
1983, Wien, Facultas Verlag 
30. Shenai JP, Borum PR. Tissue carnitine reserves of newborn infants. Pediatr Res 1984; 18' 
679-681 
31. Penn D, Ludwigs В, Schmidt-Sommerfeld E, Pascu F. Effect of nutrition on tissue carnitine 
concentrations in infants of different gestational ages Biol Neonate 1985; 47: 130-135 
32 Ontell M. The growth and metabolism of developing muscle. In Jones, CT ( Ed.). 
Biochemical development of the fetus and neonate Elsevier Biomedical Press 1982; 213-247 
33 Evans OB Muscle pyruvate oxidation following denervation and remervation. Muscle Nerve 
1983, 6- 557-560 
34. Booth RFG, Patel ТВ , Clark JB. The delcvopmcnt of enzymes of energy metabolism in the 
brain of a precocial (guinea pig) and non-precocial (rat) species J Neurochem 1980, 34. 17-
25 
35. Burleigh IG. On the cellular regulation of growth and development in skeletal muscle Biol 
Rev 1974; 49 267-320 
36. Palmer PG, Dubowit/ LMS, Verghete M, Dubowit/ V. Neurological and neurobchavioural 
differences between preterm infants at term and full-term newborn infants. Neuropediatncs 
1982; 13: 183-189 
37. Piper MC, Byme PJ, Pinell LE. Influence of gestational age on early neuromotor develop­
ment in the preterm infant. Am J Pennat 1989, 6. 405-411 
38. Minchom PE, Dormer RL, Hughes IA, Stansbie D, Cross AR, Hendry GAF, et al. Fatal 
infantile mitochondrial myopathy due lo cytochrome с oxidase deficiency J Neurol Sci 1983, 
60: 453-463 
39. Dawson KL, Geller ER, Kirkpatrick JR Enhancement of mitochondrial function in sepsis. 
Arch Surg 1988, 123 241-244 
40. Vary TC, Siegel JH, Nakatani T, Sato T, Aoyama H. Regulation of glucose metabolism by 
altered pyruvate dehydrogenase activity I Potential site of insulin resistance in sepsis. J 
Parent Enter Nutr 1986, 10 351-355 
41. Eleandcr A, Idstrom J P, Holm S, Schcrstcn T, Bylund-Fellemus AC Metabolic adaptation to 
the reduced muscle blood flow. II Mechanisms and beneficial effects. Am J Physiol 1985; 
249 E70-E76 
42. Yoshino M, Kato K, Murakami K, Katsumata Y, Tanaka M, Mon S Shift of anaerobic to 
aerobic metabolism in the rats acclimatized to hypoxia. Comp Biochem Physiol 1990; 97: 
341-344 
43. Kerr DS, Berry SA, Lusk MM, Ho L, Patcl MS. A deficiency of both subunits of pyruvate 
dehydrogenase which is not expressed in fibroblasts. Pediatr Res 1988; 24. 95-100 
44. Ho L, Wexler ID, Kerr DS, Patel MS Genetic defects in human pyruvate dehydrogenase. 
Ann New York Acad So 1989; 573: 347-359 
51 
C H A P T E R 4 
DEFICIENCY OF THE α AND β SUBUNITS OF 
PYRUVATE DEHYDROGENASE IN A PATIENT WITH 
LACTIC ACIDOSIS AND UN 
EXPECTED SUDDEN DEATH 
W. Speri, W. Ruitenbeek , Ç.M.C. Kerkhof R.C.A. Sengers , J M F Trijbels. 
J.P. Guggenbichler", A.J M. Janssen , and J.A J.M. Bakkeren 
Department of Pediatrics, University of Nijmegen, Nijmegen, The Netherlands 
Childrens' Hospital, University of Innsbruck, Innsbruck, Austria. 
Eur J Pediatr 1990. 149: 487-492 
52 
Abstract: 
An infant with moderate muscular hypotonia and congenital lactic acidosis 
died suddenly at the age of 3 months. Autopsy revealed no abnormalities res­
ponsible for this unexpected death. Measurement of mitochondrial enzymes 
involved in energy production indicated a severely decreased total pyruvate 
dehydrogenase complex (PDHC) activity in muscle tissue (0.23 nmoles. mm '. 
mg protein ', control range 2.8-8.7) and moderately decreased PDHC activity in 
fibroblasts (0.27 nmoles. mm '. mg protein ', control range 0.37-2 32) The 
activity of the first component El (pyruvate dehydrogenase) in muscle tissue 
was ten times lower than that for the controls (0 008 nmoles. mm '. mg protein 
', control range 0.10-0.25); the activities of E^ and various other mitochondrial 
en/ymes were within the normal range. Immunochemical analysis in skeletal 
muscle tissue and fibroblasts demonstrated a decrease in the amount of the α 
and β subumts of Ε,.ΤΙιε features of this patient are compared with those of 
other patients reported in the literature with immunochemically confirmed com­
bined Ε, α and β deficiency. 
Introduction: 
Lactic acidosis in the early postnatal period can be caused by tissue hypoxia 
due to circulatory or respiratory dysfunction or by various metabolic aberrati­
ons such as defects in gluconeogenesis or in the pyruvate oxidation pathway A 
frequently occurring disturbance in the latter group of lactic acidosis is a defect 
in the pyruvate dehydrogenase complex. This multienzyme complex consists of 
multiple copies of three catalytic cn/ymes: pyruvate dehydrogenase (PDH, E)), 
dihydrolipoyl transacetylase (E2) and dihydrolipoyl dehydrogenase (E^), an 
additional protein X and two regulatory enzymes (PDH kinase and PDH phos­
phatase). Defects in this multienzyme complex are most commonly caused by a 
defect in the first component, pyruvate dehydrogenase (E,) (25). The El com­
ponent has two distinct subumts, Ε,α (Mr= 41 kDa) and Ε, β (Mr=36 kDa) and 
is a tetramer (OLJ $2)-
This article reports on a patient with a fatal course of congenital lactic acido­
sis and lowered EL activity with diminished immunorcactivity of the Ejot and 
Ε,β subumts in both fibroblasts and muscle tissue and is intended as a further 
contribution to the discussion of clinical heterogeneity and varying tissue 
expression of PDHC (E,) deficiency. The data of our patient are compared with 
those of other patients with immunochemically established E, deficiency. 
Case report: 
A A, a male infant, was bom at term to non-consanguineous Turkish parents 
after an uncomplicated pregnancy and delivery. The weight at birth was 2260 g, 
the Apgar scores were 8/9/10 There were two healthy siblings, and the family 
history revealed no abnormalities.Twelve hours after birth the child was admit-
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ted to the neonatal intensive care unit with tachypnea (respiratory rate 80/min), 
anemia (Hb 6 6 mmol/1) and metabolic acidosis (pH 7.29, рСОз 2.3 kPa, base 
excess -17.7 mmol/1, bicarbonate 11 4 mmol/1). Further investigation revealed 
markedly elevated blood lactate and pyruvate concentrations (18.8 mmol/1 and 
0.61 mmol/1) and a lactate/pyruvate ratio of 30. The urinary organic acid pat­
tern determined by capillary gaschromatography showed severe lactic aciduria 
without elevation of other organic acids. Glucose levels in blood were normal. 
Lumbar puncture and measurement of CSF lactate was not performed After 
two weeks the patient still required continuous bicarbonate supplementation. 
Lactate and pyruvate levels were now 4.0 mmol/1 and 0.25 mmol/1, 3 times the 
upper limit of the control range. The lactate/pyruvate ratio was normal. Total 
carnitine concentration in serum was 21 μτηοΐ/ΐ (η > 25), free carnitine 13 
μιηοΐ/ΐ (η >20). The metabolic acidosis was well controlled by oral substitution 
of bicarbonate (5-15 mmol/day). L-camitine was supplemented in a dosage of 
300 mg/kg/day). The infant was thriving at a normal rate. The administration of 
biotin (30 mg/day) and thiamine (300 mg/ day) were without influence on lactic 
acidosis. EEG revealed 2 epileptogenic foci bilaterally in the temporal regions. 
Sonography of the skull found only a slightly enlarged ventricular system. The 
child has been kept in clinical observation because of metabolic acidosis and 
social indication. Without any preceding clinical signs the patient was found 
dead in his bed at the pediatric ward at the age of three months Muscular tis­
sue was obtained immediately after death and stored in liquid nitrogen Light 
and electron microscopy of skeletal muscle showed accumulation of large amo­
unts of glycogen and lipid droplets between myofibrils. Mitochondria were 
small with poorly developed enstae. Autopsy revealed no abnormalities 
Biochemical studies: 
Materials and Methods: 
Chemicals: [1-14C| pyruvate, sodium salt, was obtained from New England 
Nuclear, Dreieich, FRG (10 μΟ/μιηοΙ). Pyruvate, sodium salt, and thiaminepy-
rophosphate chloride (TPP) were from Boehnnger Mannheim GmbH, 
Mannheim, FRG. Tris (Tris(hydroxymethyl)ammomethane) was from Fluka 
A G., Buchs, Swit7erland. Hyamine (hydroxide of hyamine*l()-x) was purcha­
sed from Packard Becker BV, Groningen, The Netherlands, and Beta-count 
from J T. Baker Chemicals BV, The Netherlands. Other chemicals used were of 
analytical grade. 
The post-nuclear muscle supematants were prepared according to bischer et 
al (7). Before use radioactive pyruvate was freeze-dned and stored at -20° С in 
small ahquots as dry sodium salt sealed under nitrogen. The purity of the radio­
active pyruvate was determined by high voltage electrophoresis (34). 
Enzyme assays: Total PDHC activity in muscle tissue was determined by 
measuring the "СО^ production with [1-I4C] pyruvate, according to the method 
of Van Laack et al. (31) with minor modifications. Incubation was earned out 
in 100 mmol/1 Tris buffer containing 0.5 mmol/1 EDTA, 4 mmol/1 MgC^, 2 
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mmol/1 CaCl2, 0.5 mmol/1 NAD
+
, 1 mmol/1 TPP, 2 mmol/1 CoASH, 0.08 
mmol/1 cytochrome с, 5 mmol/1 L-camitine, pH 7.4 and 10 μΐ of an NADH : 
cytochrome с oxidoreductase preparation (9). This preparation had a stimula­
ting influence on en/yme activity. 50 μΐ of homogenate were added to the incu­
bation mixture. After preincubation for 10 mm at 37 °C, incubation was started 
by addition of |1- I 4C| pyruvate solution (specific activity 0.9 μΟ/ μιηοΐ) to a 
final concentration of 0.5 mmol/1. The final volume was 0.5 ml. Blank values 
were obtained by replacing supernatant by SETH medium (250 mmol/1 sucrose, 
2 mmol/1 EDTA, 10 mmol/1 Tns-HCl (pH 7.4 at room temperature), 50 U/ml 
heparin). These blanks produced essentially the same amount of background 
counts as the test mixture in the presence of the specific inhibitor fluoropyruva-
te. Incubation was performed at 37°C in 20 ml glass scintillation vials sealed by 
rubber stoppers. The vials contained two small glass tubes, one inside the other, 
the inner one containing 0 2 ml hyamine hydroxide. After 20 mm at 37 CC , the 
reaction was terminated by addition of 0.2 ml of 3 mol/1 perchloric acid. The 
14
 CO2 liberated was trapped in hyamine during 60 mm at 0 0C The radioac­
tivity of the 14 CO2 was measured at 4 °C in 5 ml Beta-count in a Searl Mark III 
scintillation counter 
The assay for PDHC activity in cultured fibroblasts was based upon the 
method described by Robinson et al (23). The suspension of 25 χ 10" cells per 
ml 0.1 mmol/1 potassium phosphate, pH 7.4, was three times frozen-thawed. 
For measurement of basal PDHC activity the suspension was 1:1 diluted with 
UK) mmol/l potassium phosphate, pH 7.4. For measurement of total PDHC 
activity the suspension was 1:1 diluted with 50 mmol/1 Tris, pi I 7.4, 30 mmol/1 
MgCl2 , 1 mmol/1 CaCl2, 0.08 mmol/1 TPP and 4 mmmol/1 dichloroacetate 
(DCA)(27), and prcincubatcd at 37° С during 10 minutes. 
The incubation mixture was composed by adding 50 μ] 19 mmol/1 NAD and 
50 μΐ 1.2 mmol/1 TPP to 200 μΐ of a 100 mmol/1 potassium phosphate buffer, 
containing 1% BS A , 2mmol/l EDTA and 0.5 mmol/1 CoASH, pH 7 4 For the 
incubations of total activated PDHC 50 μΐ 20 mmol/1 MgC^ was added. After 
addition of 100 μ] cell suspension and a 2 mm preincubation period the reaction 
was started by 50 μ] of a 3 mmol/1 [1-'4C| pyruvate solution (specific activity 
about 1.6 μΟ/ μτηοΐ). After incubation at 37° С during 15 min incubations were 
stopped and processed as described above. Blanks contained buffer instead of 
cell homogenate. 
E, activity was measured as recently described by Van Laack et al (31), Е^ 
activity according to Hayakawa et al (11) at a lipoamide concentration of 2 
mmol/1. The activity of various respiratory chain en/ymes was measured in 
skeletal muscle homogenate as previously described (8). Cytochrome с oxidase 
activity was determined according to Cooperstein and Lazarow (3), citrate synt­
hase activity according to Srere (28). Unless otherwise stated, all procedures 
were carried out at 0-4°C. Protein was measured by the method of Lowry et al 
using bovine serum albumin as a standard (20). 
Immunochemical studies: Muscle supernatants and fibroblast homogenates 
were analyzed by immunochemical methods SDS-polyacrylamide gel electro­
phoresis was performed on 10-15% gels m the Phast-system equipment 
(Pharmacia/ LKB Uppsala, Sweden) using the buffer system as described by 
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Laemlli (19). The separated proteins were transferred to nitrocellulose membra­
nes essentially as described by Towbin et al (30). Proteins were stained with 
Ponceau S (Sigma Chemical Co., St. Louis, MO). Then nitrocellulose membra­
nes were washed and incubated with antiserum raised in rabbits against bovine 
heart pyruvate dehydrogenase complex (Sigma Chemical Co., St. Louis, MO). 
Antigen-antibody complexes were detected according to standardized techni­
ques using horseradish peroxidase labelled porcine anti-rabbit serum as second 
ligand and 3,3'-di-amino- benzidine as substrate. Finally, the immunoblots 
were scanned with a laser densitometer (Ultrascan XL, Pharmacia/ LKB 
Uppsala, Sweden). 
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Figure 1: Immunoblot analysis of PDHC in muscle supemalants and fibroblast homogenales from 
the patient and controls. Lanel: molecular weight standards stained with Ponceau S and marked 
with a pencil. Lane 2: control muscle supernatant (1.4 μg prot.). Lane 3: muscle supernatant from 
the patient (1.9 μg prot.). Lanes 4 and 6: control fibroblast homogenales (2.1 μg. 1.9 μg prot.). 
Lanes 5 and 7: two different fibroblast suspensions from the patient (2.3 and 2.8 μg prot.). Lane 8: 
purified bovine PDHC (0.02 μg prot.). 
Results: 
The activity of activated PDHC and its E, component in muscle tissue of the 
patient was less than 10% of the lower limit of the control range, while E^  com­
ponent showed normal activity (Table 1). Numerous other enzymes of the 
respiratory chain, e.g. NADH: Q| oxidoreductase, succinate : cytochrome с oxi-
doreductase and cytochrome с oxidase, had (low) normal activity. 
The activity of the basal and stimulated PDHC in fibroblasts were lowered in 
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comparison with control values, stimulated PDHC showing a high residual 
activity of 68% of the lower limit of the control range (Table 2). Cytochrome с 
oxidase, citrate synthase and pyruvate carboxylase had a normal activity in 
fibroblasts. 
Eta ;: 
Figure 2' Densitometrie bcannmg of the immunoblot analysis in figure I : 
a) Densitometrie traces of lane 2 (control muscle supernatant,! 4 № prot.) and lane 3 
(muscle supernatant from the patient (1 9 |ig prot.) and b) lane 4 (control fibroblast homogena-
te 2.1 μg prot.) and lane 5 (fibroblast suspension from the patient (2Л |ig prot.) 
Immunoblot analysis of muscle supernatant and fibroblast homogenate from 
the patient was compared with controls with normal PDHC activity (Fig 1). In 
our electrophoretic system the E2 protein in the suspensions appeared to have a 
molecular mass between 70 and 78 kDa, the X protein between 48 and 50 kDa, 
the Ε
ι
α protein between 42 and 44 kDa, the E ^ protein between 34 and 37 
kDa. The band of the E3 protein is hardly visible in most immunoblots (it has a 
low immunogenicity, if PDH complex is used as antigen (5) ), but if visible, the 
apparent molecular mass is 53-56 kDa. 
The antibody reacted with some unidentified antigens, especially in muscle 
tissue with a protein of molecular weight 97 kDa. Both muscle and fibroblast 
homogenates exhibited significantly decreased amounts of both subunits Ε,α 
and β, the defect being more pronounced in muscle tissue than in fibroblasts. 
The densitometric patterns support this conclusion in a more quantitative way 
(Fig 2 a and b). 
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Table 1: Enzyme adivines and carnitine concentration in muscle tissue: 
En7yme 
Pyruvate dehydrogenase complex* 
Pyruvate dehydrogenase (E,)* 
E, (ofPDHQ* 
NADH: Q, oxidoreductase 
Succinate: cytochrome с oxidoreductase 
Succinate dehydrogenase 
Cytochrome с oxidase 
Citrate synthase 
Camiline, non-eslerfied 
Carnitine, total 
Patient 
0.23 
О.ШК 
92 
4.3 
8.0 
8.3 
73 
65 
I.I 
1.9 
Controls 
m ± SD 
5.1+2.3 
0.15+0.06 
111 ± 34 
9 4 ± 4 
18±7 
8 + 3 
194 ±92 
77 ± 33 
3.2+ 1.1 
3.1 ±0.5 
Range 
2.8-8.7 
0.10-0.25 
65-199 
4.4-18.9 
10-33 
3 6-15 
73-284 
48-146 
2 . 2 ^ 2 
2.7^16 
η 
5 
5 
21 
17 
9 
9 
39 
18 
21 
21 
* Activities measured in total muscle homogenale, other activities measured in 600 g supernatant of 
the homogenate. 
Enzyme activities expressed as nmoles . ' . mg protein ' 
Carnitine concentration in limóles . g muscle 
Table 2: Enzyme activities in cultured skin fibroblasts 
Enzyme 
Cytochrome с oxidase 
Citrate synthase 
Pyruvate carboxylase 
Pyruvate dehydrogenase complex, 
basal 
Pyruvate dehydrogenase 
activated 
complex, 
Patient 
29 
41 
1.1 
0.16 
0.27 
Controls 
m ± S D 
25.4 ± 10.1 
36 4 ± 10.7 
1.25 ±0.4 
0.75 ± 0.4 
1.1 ±0.5 
Range 
9 8^t7 
14-53 
0 57-2 6 
0.35-1.5 
0.37-2.32 
η 
26 
26 
41 
18 
23 
Values expressed in nmoles . mm ' . mg protein 
Discussion: 
In most of the cases of pyruvate dehydrogenase (E,) deficiency so far repor­
ted, only enzyme measurement has been performed, fibroblasts being the tissue 
most frequently investigated. This article reports on a patient with fatal lactic 
acidosis where it was possible to obtain both enzymatic confirmation of Ej 
deficiency and immunochemical demonstration of a combined deficiency of 
both subunits of the first component of the PDH complex in muscle tissue and 
fibroblasts as well. 
Table 3 summarizes the features of this patient and other patients with Eia 
and β deficiencies for whom enzymatic and immunochemical findings have 
been reported in the literature. Recently Robinson et al summarized clinical and 
biochemical data from 30 patients with enzymatically proven E, deficiency and 
found only a poor correlation between enzyme activities and clinical course 
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(26). No distinct clinical entities could be established. Our comparison of the 
patients with examinations at subunit level (table 3) and even at m RNA level 
(32) also fails to show a good correlation between clinical course and extent of 
the defect. The majority of the patients listed in table 3 demonstrated a fatal 
course of the disease with central nervous system involvement and striking 
brainstem problems, including respiratory difficulties. Some patients with a 
combined E! a and Ε,β deficiency seem to belong to the group with a fatal 
course of the disease, some with the characteristics of neuropathologically pro­
ven subacute necrotizing encephalomyelopathy (Leigh's disease). Two patients 
are reported to have a milder course of the disease. 
Table 3. Patients with immunochemically confirmed Ε,α and Ε,β deficiency and lactic acidosis 
Patient 
1 
2 
3 
4 
5 
6 
7 
8 
Sex 
m 
m 
m 
m 
f 
m 
m 
m 
Age of 
onset 
5 months 
Birth 
2.5 months 
12 months 
Birth 
N.m. 
N.m. 
Birth 
Dealh 
2 years 
1 year 
8 years 
18m 
1 m 
Alive 
14 years 
Alive 
8 years 
3 m 
Clinical 
symptoms 
Weakness, seizures, 
ataxia, hypotonia, 
respiratory 
msulficiency 
Hypotonia, secures 
apnoeic spells 
Neuropatho-
logical 
findings 
Leigh 
Central hypoventilation Leigh 
syndrome, ataxia, 
ophthalmoplegia, seizures 
Weakness, seizures, 
hypotonia, respiratory 
insufficiency 
Hypotonia, apnoea 
Ataxia, seizure 
. disorder 
Ataxia, developmental 
delay 
Hypotonia, apnoea 
Tissue Reference 
affected 
Muscle, 15 
heart, liver, 
kidney, 
fibroblasts* 
Lympho- 14 
cytes, fibroblasts, 
muscle, heart, 
kidney, liver 
Fibroblasts 12,13, 
18 
Skeletal 1 
muscle, liver 
Fibroblasts 2 
Fibroblasts 32 
Fibroblasts 32 
Skeletal This 
muscle, report 
fibroblasts 
* no deficiency in fibroblasts 
η m.= not mentioned 
The death of our patient at the age of three months was sudden and unexpec­
ted. Unfortunately brain tissue was not available for biochemical investigation. 
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However, if we assume, on the basis of the expression of the defect in fibrob­
lasts and muscle tissue, a systemic involvement, sudden death could be an 
expression of the central nervous system involvement (26) in Et deficiency. In 
general, diminished energy production due to pyruvate dehydrogenase deficien­
cy leads to a drop in high energy phosphate metabolites in affected cells. 
Stimulation of glycolysis results in intracellular accumulation of lactic acid 
which curtails glycolytic ATP production and may result in cell death The 
areas of the brain most susceptible to this type of damage are those that rely 
most on oxidative energy ι e the basal ganglia, thalamus and the brain stem 
(22), which is pathogenetically involved in sudden death by respiratory arrest. 
Other patients with disturbances of the mitochondrial energy mechanism have 
also been mistakenly regarded as sudden infant death syndrome (SIDS) patients 
(10) Sudden unexpected death also occurred in two patients mentioned by 
Wexler et al. (32) in a description of patients with E[ deficiency documented at 
subunit and mRNA level. 
Eight patients with immunochemically confirmed E^ deficiency were found 
to have combined Ejoi and Ε,β deficiency (table 3). In several other patients an 
abnormality only in the a chain was reported (4,16,17, 21,33) Other patients 
showed normal immunoreactive El subumts but abnormal b | activity (24, 32). 
It is striking, that only a or combined deficiencies have been so far detected in 
patients with E, deficiency Because the phosphorylation site for regulation of 
the whole complex is situated on the E | a chain, it may be that defects of the a 
subunit play a crucial role in the pathogenesis of the clinical pattern of E] defi­
ciency If this is true, a defect involving the β chain would not have the same 
severe consequences as a lack of immunoreactive a chain or a disturbance in its 
phosphorylation (33) 
One explanation for a combined Ej« and β deficiency could be, that the 
mutation ol a gene ot one subunit of Ej results in a disturbance of the transport 
of the subumts into the mitochondria or disturbed assembly of the tetramer or 
further attachment to the E2 core, possibly leading to degradation of the unasso-
ciated polypeptides. If this is the case, the detection of normal amounts of 
immunoreactive E ^ subumts in isolated Ε,α deficiencies is difficult to explain. 
Studies by Wexler et al. (32) in a number of patients with E, deficiency 
detected a group with diminished amounts of Ε,α and β but reduced levels of 
mRNA for £[01, whereas the amount of mRNA for Ε,β was normal The same 
study also desenbes two other types of mutation, one with immunologically 
detectable Ε,α and Ε,β and normal mRNA levels, the other with diminished 
amounts of both immunoreactive proteins but normal levels of mRN As for both 
subumts. A fourth type might be an isolated Ε,α deficiency, which has been 
clearly demonstrated in a patient by cloning of the defective gene (6). 
In addition to the molecular explanation of the pathogenesis and heteroge­
neity of subunit deficiencies, many questions remain concerning the methodo­
logy of PDH complex measurement (29) and tissue-specific expression of 
defects of the complex (14,15) 
Recently it has been established that fibroblasts do not reflect the accurate 
status of PDHC in other tissues One patient has been described with Ε,α and 
Ε,β deficiency in skeletal muscle, heart, liver and kidney but no expression of 
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the defect in fibroblasts (15). The defect in our patient was found enzymatically 
and immunochemically in fibroblasts and muscle tissue, other tissues were not 
available for investigation. Repeated enzyme measurements revealed high resi­
dual activities of PDHC in fibroblasts (68% of the lower limit of the control 
range), but severe deficiency in muscle tissue (<10%). Likely also the PDHC 
activity in fibroblasts of our patient does not reflect the residual activities in his 
other tissues. 
Better evaluation of defects in the mitochondrial energy production will 
require a combination of enzyme studies and immunochemical analysis of the 
components of the oxidative route. Determination of PDHC activity in fibrob­
lasts alone is inadequate in the majority of patients where PDHC deficiency is 
suspected. 
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Introduction: 
Tissue specificity of defects in the intrarmtochondnally localized energy 
generating system is observed mainly in patients with deficiencies of the respi-
ratory chain (for review see Capaldi R A. et al (1988) and has also been descri-
bed recently in pyruvate dehydrogenase deficiency (Kerr OS. et al (1988). 
Heterogeneous tissue expression of mitochondrial defects may be reflected in 
the onset and severity of the disease, the clinical course and specific symptoms 
An important practical question is the choice of the tissue, which should be 
investigated in patients in whom a mitochondrial disorder is suspected 
Clinically these patients present often with a multisystem involvement. It is a 
common policy, first to perform biochemical investigations in muscle tissue of 
patients suspected to suffer from a mitochondrial (encephalo)myopathy. This 
has several reasons· skeletal muscle tissue is rich in mitochondria due to its 
high energy demand Furthermore it appears, that mitochondrial defects are 
more frequently expressed in muscle tissue than in other tissues Finally muscle 
biopsy is, besides skin biopsy, a less severe intervention in patients compared 
to other organ biopsies. 
In order to get further insight in tissue specificity of mitochondrial defects, 
the results of enzymalical investigations of 14 patients with an established 
defect in the mitochondrial energy generating system in skeletal muscle and in 
whom at least one other tissue has been examined, are presented. The residual 
activities of the affected en/ymes in the various tissues are compared 
Methods 
The activity of vanous respiratory chain enzymes was measured in skeletal 
muscle homogenate as described by Fischer et al (1986), PDHC activity in 
muscle tissue and fibroblasts according to Speri et al (1989). The same 
methods were used for enzyme measurements in brain and liver, but these tis-
sue specimens were homogenized in SEF medium (250 mmol/1 sucrose, 2 
mmol/1 EDTA, 10 mmol/1 KH2PO4, pH 7 4) Homogenate was prepared from 
frozen tissues, only in patients 5, 11 and 12 homogenate was prepaied from 
fresh muscle tissue 
Results and discussion: 
In 14 patients with an established defect in the mitochondrial energy genera-
ting system in muscle tissue, the distribution of the defect in other tissues such 
as liver, brain and fibroblasts has been investigated (see table 1) Defects found 
in muscle tissue are not always expressed in other tissues. In 9 of the 14 pati-
ents the defect could be demonstrated in liver and/or fibroblasts, too. Although 
some patients (Nr. 2,5,7,12) show similar residual activities in their investiga-
ted tissues, in the majority of patients the residual activity varies to a large 
extent between different tissues. In patient Nr. 13 and 14 with a combined defi-
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ciency, the ratio of the activity of the defective enzymes in muscle strongly dif­
fers from liver. Five patients with an enzyme defect in liver presented with a 
multisystem disease showing signs of moderate liver dysfunction and central 
nervous system involvement. Interestingly both patients with normal activities 
in liver tissue had no or only a minimal lactic acidosis but clear elevations of 
lactate in cerebrospinal fluid. A possible explanation for the lack of severe 
metabolic acidosis in these patients with " cerebral" lactic acidosis (Brown 
G.K. et al., 1988) can be, that accumulating lactate in muscle tissue is further 
metabolized in the unaffected liver. 
Table 1. Mitochondrial en/ymc activities in patient tissues (values given as percentages of the 
mean of control values) and in control tissues 
Patient Defect 
Single enzyme defeds: 
1 PDHC 
2 PDHC 
3 PDHC 
4 1 
5 I 
6 sec 
7 SCC 
8 IV 
9 IV 
Combined clefet is 
10 I/IV 
11 I/IV 
12 I/SCC/IV 
13 l/SCC 
14 l/SCC 
Muscle 
6* 
20* 
52* 
37* 
3* 
37* 
19* 
4* 
13* 
12*/12* 
11*/14* 
22*/25*/10* 
2*/14* 
14*/30* 
Tissue 
Liver 
-
-
26 
0* 
0* 
5* 
22* 
-
-
-
-
-
I7*/13* 
99/106 
studied 
Hbroblasts 
24* 
21* 
26* 
n.m. 
n.m. 
η m. 
n.m. 
91 
47 
n.m /97 
n.m./74 
π m./n m 
n.m. 
n.m. 
./12* 
Brain 
-
-
-
14* 
-
-
-
-
-
-
-
-
-
-
Cannai liuuei 
Enzyme Muscle Liver Fibroblasts Brain 
PDHC lolal 
1 
SCC 
IV 
2 8-8 7** 
5 1±2 3(n=5) 
8.7-25 3 
18+5.0 (n=ll) 
22-84' 
50+18(n=18) 
73-284 
194+92(n=3H) 
4.2-15.2: 
8.3+3.9 (n=6) 
0 38 -7 5 
1 9+1.8 (n=24) 
4 7-9 2 
7 2±l7(n=7) 
6 0-50.4 
20+15.3 (n=9) 
13 9-108 
5()±27 6(n=ll) 
0.37-2.4 
1 1+0.5 (n=23) 
nm 51-181 
η m 10 8+5 1 (n=5) 
η m 
n.m. 
9 8-47 
25.4+10 1 (n=26) 
Control values are expressed in nmol mm"1 mg protein" 
I = complex I (NADU: Q oxidoreduclase) 
SCC = succinate, cytochrome с oxidoreduclase 
IV = cytochrome с oxidase 
PDHC = pyruvate dehydrogenase complex 
Values for 'fresh (pat .12) and ^ frozen 
muscle (issue 
* deficient value 
η m = technically not measureable 
- = nol measured 
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It is difficult to comment on the expression of mitochondrial defects in cultu­
red fibroblasts because investigations in fibroblasts have some restriction: 
PDHC and cytochrome с oxidase can be measured technically in an adequate 
manner. At least in our experience attempts to measure NADH: Q, oxidoreduc-
tase and succinate: cytochrome с oxidoreductase have been unsuccessful!. High 
levels of NADH: cytochrome b5 oxidoreductase in fibroblasts makes it impossi­
ble to monitor accurately the rotenone sensitive component of NADH: Q, oxi­
doreductase (Robinson B.H. et al., 1985). Cytochrome с oxidase deficiency was 
not present in fibroblasts from 4 of 5 patients with a defect in complex IV in 
muscle (whether or not in combination with a complex I defect). Fibroblasts do 
not reflect the accurate status of enzymes of the pyruvate oxidation pathway in 
other tissues (Kerr D.S. et al., 1988, Schölte H.R. et al., 1987) and in the majo-
rity of our patients higher residual activities were found. 
In conclusion the data of our patients indicate, that for diagnostic purposes 
muscle tissue is preferable to other tissues in patients with mitochondrial defec-
ts in the pyruvate oxidation route. Nevertheless it is possible, that in a minority 
of cases defects are solely expressed in non-muscular tissues (Prick M.J.J, et 
al., 1982). In patients 3 and 4 the high residual activities in muscle tissue did 
not permit initially a clear conclusion and the diagnosis was supported by mea-
surements in other tissues. In patients with severe clinical findings indicating a 
mitochondrial disorder and no biochemical abnormalities in muscle tissue, 
investigation in as many tissues as possible should be carried out. At the pre-
sent stage of knowledge on tissue specificity, enzyme studies should be combi-
ned with immunochemical investigations in order to define the defect at the 
subunit level and to gain a better insight into the involvement of nuclear and/or 
mitochondrial encoded proteins in the various defects. Our selection of patients 
with different tissue distribution of the mitochondrial defect is a basis for furt-
her application of DNA techniques in the different tissues of these patients. 
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Abstract: 
In six patients with mitochondrial (encephalo)myopathy investigations of 
skeletal muscle revealed a defect of pyruvate dehydrogenase complex (PDHC) 
in combination with one or more respiratory chain complex deficiencies. A 
combination of defects of this kind has not been reported previously. Five of 
the six patients presented within the first year of life and had a severe clinical 
course. Intrafamiliar variability of the clinical course in dizygotic twins with 
both suffering from a COX deficiency and one of them also from a PDHC defi­
ciency suggests an additional effect of PDHC deficiency on the clinical sym­
ptoms. Immunoblot studies of PDHC in five of the patients revealed no abnor­
malities in their subunit pattern, rendering a defect of mitochondrial protein 
import or assembly unlikely. The finding of a combined PDHC and respiratory 
chain deficiency has implications for the diagnostic approach, for therapy and 
genetic counselling. The exact pathogenetic mechanism of this combination of 
defects remains to be elucidated. 
Abbreviations: 
PDHC = pyruvate dehydrogenase complex; E! = pyruvate dehydrogenase; 
E3 = dihydrolipoyl dehydrogenase; COX = cytochrome с oxidase; CS = 
citrate synthase; SCC = succinate: cytochrome с oxidoreductasc; SDS-PAGE = 
sodium dodecyl sulphate- Polyacrylamide gel electrophoresis 
Introduction: 
Defects of the respiratory chain arc the most common cause of mitochon-
driopathies. At first, patients with a deficiency of only one of the respiratory 
chain complexes were described in the literature (for review see ref.17). 
Recently, combined deficiencies of the respiratory chain complexes have been 
observed in patients with mitochondrial myopathies (8,11), most commonly 
combined deficiencies of complex I (NAD^Q, oxidoreductasc) and complex 
IV (cytochrome с oxidase). Deficiencies of the pyruvate dehydrogenase com­
plex (PDHC) form another group of mitochondrial myopathies manifesting 
with lactic acidosis and a variable clinical picture ranging from early death in 
infancy to a more moderate clinical course (10). 
In this paper we report clinical and biochemical data from 6 patients with a 
combined PDHC and respiratory chain deficiency in muscle tissue. These fin­
dings have consequences for the diagnostic procedure, for therapeutical 
approach and for genetic counselling. 
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Case reports: 
Patient 1 , a girl, was bom at term to healthy non-consanguineous parents 
(birth weight 3200 g, Apgar scores at one and live minutes 9/10). The family 
history was unremarkable. At the age of 6 weeks, generalized clonic seizures of 
short duration (10-20 sec) were noted. In spite of treatment with valproate, the 
frequency of the seizures gradually increased, and the child developed general 
hypotonia and feeding difficulties. A CT scan of the brain showed symmetrical 
hypodensities of the basal ganglia. Brainstem audiometry showed low or no 
response. Visual evoked potentials were normal. Laboratory investigations sho­
wed elevated levels of blood lactate (3.8 mmol/1, normal < 2) and blood pyru­
vate (0.19 mmol/1, normal < 0.12) and serum alanine (1052 |imol/l, normal < 
690). Lactate was also elevated in CSF (6.5 mmolA, normal < 1.8). The child's 
condition deteriorated rapidly and she died of respiratory failure at the age of 
two months. Muscle biopsy was taken immediately after death but histopatho-
logical examination was not carried out. Postmortem histological examination 
of the brain was consistent with the diagnosis of Leigh disease, showing spongy 
degeneration and vascular proliferation in the basal ganglia, pons, thalamus and 
spinal cord. 
Patient 2 was the third son of consanguineous parents; two older children 
died in the neonatal period. The child was admitted to hospital at the age of 3 
months because of feeding difficulty, weakness, floppiness and lack of ocular 
fixation. Laboratory investigation showed metabolic acidosis with elevated 
blood lactate (5.1- 8.8 mmol/1) and blood pyruvate (0.14 -0.34 mmol/1) and lac­
tic aciduria. Hyperammonaemia was also present (105-230 μπιοΐ/ΐ, normal < 
50). At the age of 4 months, assisted ventilation was necessary because of 
respiratory failure.Therapy with biotin (10mg/day), carnitine (150 mg/kg/day), 
riboflavin (100 mg /day ) and thiamine (300 mg/day) was without clinical bene­
fit. Muscle biopsy was performed at 4 months. Histological examination revea­
led a lipid storage myopathy. On electron microscopy increased mitochondria 
with abnormal cristae were observed, but no crystalline inclusions were found. 
The patient died at the age of 8 months from an infection of the respiratory 
tract. 
Patient 3 , a girl, was bom at term to non-consanguineous healthy parents 
(2850 g, Apgar scores 8 and 9 at one and five minutes). Fetal tachyarrhythmia 
had been noted since the 37 th week of gestation. A double outlet right ventricle 
with pulmonary atresia required the implantation of a modified Blalock 
Taussig shunt. In the first few weeks of life, recurrent attacks of metabolic aci­
dosis (pH= 6.8 - 7.0, base excess -13 to -30 mmol/1) were accompanied by high 
urinary excretion of lactic and 2-oxoglutaric acid, severe liver dysfunction and 
hepatocellular fatty degeneration. Myocardial insufficiency was observed 
during one attack, but otherwise no major cardiac problems occurred. 
Histological and ultrastructural examination of a muscle biopsy specimen obtai­
ned at 5 weeks showed no abnormalities. After therapy with a kelogenic diet 
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and thiamine substitution, clinical improvement was observed and no further 
metabolic crises were observed 
Patient 4 was described in detail by Hurvit7 et al (4) The boy presented 
with a mitochondrial myopathy, a Fanconi De Toni Debré syndrome and persi-
stent galactosaemia following a galactose load m association with glycogen sto-
rage in the liver At an age of 4 years delayed gross motor development, tachy-
pnoea, hepatosplenomegaly, rickets and severe muscular hypotonia were noted 
Laboratory studies revealed lactic acidosis (pH= 7.13, HC03 = 7 mcq/1, base 
excess -20, blood lactate 6.3 mmol/1), a fasting hypoglycaemia (1 3 mmol/1), 
hypophosphataemia (0 5 mmol/1), reduced calculated reabsorption of phos-
phorus (63%), elevated alkaline phosphatase (500 U/l). Urinalysis revealed glu-
cosuria, acetonuna, bicarbonatuna and generalized aminoaciduria Histological 
examination of a muscle biopsy revealed accumulation of mitochondria in sub-
sarcollemal region with irregular pattern and dilated, elongated and distorted 
cristae (for further details see ref. 4) 
Patient 5. fourth child of healthy non consangineous parents was bom al 
term after an uneventful prcgancy. One brother died at an age of 1 1/2 years 
with progressive cerebral atrophy, tetraspasticity and convulsions. Obduction 
was refused by the parents. Diy7gotic twin siblings are healthy at the age ol 6 
years. The patient showed a normal development up to 10 months of life. At the 
age of 11 months he had a lack of ocular fixation, lost motoric skills and deve-
loped respiratory insufficiency At this time blood lactate was elevated (7.5 
mmolA) and a hyperglycaemia (31 mmol/1, normal 3 3-5 6) was found. In the 
following course lactate, pyruvate, alanine and glucose levels in serum were 
normal but lactate in CSF was found to be highly elevated (6.7 mmol/1, normal 
<1.8) CT scan of the CNS revealed symmetric hypodensities in the caput 
nucleus caudatus and in the thalamus By light and electron microscopy normal 
muscle tissue (m quadriceps) was observed without alterations of the mito-
chondria. A preliminary observation of a three months course of therapy with 
thiamine (45 mg/day), riboflavine (45 mg/ day) , lipoic acid (200 mg/day) and 
L-camitine (100 mg/kg/day) started at the age of 12 months shows slight clini-
cal improvement of motoric skills and social responsiveness 
Patient 6 , first male dizygotic twin, was bom after an uneventful pregnancy 
at 37 weeks gestation, birth weight 2600 g Initially, the child's developmental 
progress was normal, he smiled at 6 weeks and started to become interested in 
objects However, he rapidly lost these skills and subsequently made no further 
developmental progress He presented at the age of 5 months with marked 
hypotonia, poor leeding and weight loss The child was areflexic and developed 
generalized seizures and irritability Laboratory investigations revealed mildly 
elevated ammonia (70 μπιοΐ/ΐ) and slight elevation of transaminases The CK 
activity was consistently elevated (about 300 IU/1). A 12-hour fast resulted in 
elevation of lactate levels (4.9 mmol/1). 
EEG showed high voltage slow activities with sharp components indicating 
a diffuse encephalopathic process A CT scan was normal but auditory evoked 
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responses were absent At the age of two years and six months the patient has 
bulbar dysfunction and requires nasogastric tube feeding. He has severe muscu­
lar hypotonia and has developed a choreoathetotic movement disorder. He has a 
profound sensoneural deafness and intermittent generalized clonic tonic seizu­
res Muscle biopsy at 5 months revealed small vacuolated fibres with increased 
lipid content The cytochrome oxidase stain was reduced. Large abnormal mito­
chondria and a number ot disintegrated myofibrils were visible under the elec­
tron microscope. 
The patient's brother (patient 7) presented at the same time with failure to 
thrive, vomiting, and irritability. Developmental progress was uneventful until 
the age of 17 months when he also became encephalopathic during an acute 
viral infection with clouding of consciousness, loss of social awaimess, tonic 
clonic seizures involving all four limbs He was hypotonic and areflexic EEG 
showed high voltage slow activity corresponding to a diffuse encephalopathic 
process He improved slowly over several weeks although he suffered intermit­
tent generalised convulsions A CT scan of the brain was normal. At the age of 
two years and six months the patient has also bulbar dysfunction and requires 
nasogastric tube feeding In contrast to his brother he has normal strength in all 
muscular groups Also intermittent generalized clonic tonic seizures are noted 
but less severe than in his brother. 
DNA analysis using the multi-locus probe 33.15 demonstrated that the twins 
are dizygotic 
Methods: 
Muscle biopsy specimens from patients 2-7 were transported in dry ice and 
stored at -70oC until en/yme measurement. In the case of patient 1, muscle tis­
sue was removed immediately after death and stored at -7()°C as well. 
Homogcnates were prepared from frozen muscle tissue (2). NADH. Ql oxidorc-
ductase and succinate : cytochrome с oxidoreduclase activities were measured 
according to Fischer et al (3). Measurement of total PDHC activity in muscle 
tissue and Fibroblasts as well as sodium dodecyl sulphate Polyacrylamide gel 
electrophoresis (SDS-PAGE) and immunoblotting for detection of PDHC subu-
mts were performed as desenbed earlier (14). Protein was determined accor­
ding to Lowry et al. (7). Owing to the limited amount of tissue available, enzy­
me measurement of the E] and E3 subunit of PDHC was not possible. No 
immunoblot studies could be performed for patient 3 for the same reasons 
Citrate synthase was measured according to Srere (16) and cytochrome с 
oxidase according to Cooperstem and Lazarow (1) in both muscle tissue and 
cultured fibroblasts. 
Results: 
Enzyme activities in muscle tissue· The activities are summanzed m Table I 
In addition to a significant decrease in PDHC activity , 6 patients also exhibited 
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decreased activity of one or more of the complexes of the respiratory chain 
(patients 1-6 ). Patient 7 being the twin brother of patient 6 suffered from an 
obvious cytochrome с oxidase (COX) defect but had a normal PDHC activity. 
Patient 1 had a severe deficiency of both PDHC and complex I. In patient 2, the 
deficiency of PDHC was accompanied by an absence of COX activity, a defect 
in complex I, and a moderate reduction in succinate: cytochrome с oxidoreduc-
tase (SCC). Patient 3, 5 and 6 had reductions in both PDHC and COX activity. 
In patient 4, the activities of PDHC, COX and SCC were decreased to similar 
extents. Citrate synthase (CS) activity was normal to slightly increased in all 
patients. 
Table I: Enzyme activities in muscle tissue (values expressed in mU/ mg protein) of patients with 
combined PDHC and respiratory chain deficiency 
Patient 
1 
2 
3 
4 
5 
6 * 
7* 
controls: 
range 
mean ± SD 
η 
PDHC 
0.9 
1.7 
1.6 
0.9 
0.9 
1.7 
4.2 
2 8-8.3 
5.311.8 
11 
CI 
1.1 
2.4 
7.3 
5.8 
5.4 
6.1 
4.3 
4.4-19 
9.4± 4.0 
17 
SCC 
n.m. 
3.4 
59 
1.9 
nm 
6 0 
3 3 
4 2-16 
8 3±3.9 
6 
COX 
77 
n.d. 
46 
31 
39 
31 
14 
73-284 
194±92 
38 
CS 
140 
183 
56 
69 
59 
143 
255 
48-146 
80±29 
16 
PDIIC = pyruvate dehydrogenase complex 
CI = NADH Q, oxidoreductase 
SCC = succinate, cytochrome с oxidoreductase 
n.d. = not detectable 
COX = cytochrome с oxidase 
CS = citrate synthase 
n.m.= not measured 
* di¿ygotic twins 
Enzyme activities in cultured fibroblasts: Activities of PDHC, COX and CS 
have been measured in patients 1-3 and 5-7 and appeared to be normal except 
for the PDHC activily in patient 5, which was reduced (PDIIC basal: 0. 14 mU/ 
mg protein; controls: m± SD= 0.75 ± 0.4, range= 0.35-1.5, n=18 ; PDHC total: 
0.15 mU/ mg protein, controls: m±SD= 1.1 ± 0.5, range= 0.37-2.3, n=23). 
Enzyme activities of complex I and III are, at least in our hands, technically not 
reliably measurable. No skin biopsy was performed in patient 4 . 
Immunochemical studies of PDHC in skeletal muscle of patient 1, 2, 4, 5 
and 6 with SDS-PAGE and subsequent immunoblotting revealed neither abnor-
malities in the subunit pattern of the multienzyme complex nor in the total amo-
unt of the antigenic PDHC signal (results not shown). 
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Discussion: 
We describe 6 patients with a heterogeneous clinical course and heteroge-
neous biochemical data, which have in common PDIIC deficiency in combina-
tion with a defect in one or more ol the complexes of the respiratory chain m 
muscle tissue Immunochemically in the subumt pattern of PDHC in the five 
patients examined no abnormality was found Enzyme activities measured in 
cultured fibroblasts were normal except in one patient, indicating once more 
that mitochondrial enzyme delects are frequently not expressed in cultured 
fibroblasts (5,15) 
It is not possible to distinguish a PDHC deficiency from a respiratory chain 
defect on a clinical level. Both subclasses of patients show heterogeneity in cli-
nical features. Our patients with combined PDHC/respiratory chain deficiency 
likewise exhibit no specific clinical symptoms which would permit the identifi-
cation of a subgroup within the group of mitochondrial myopathies, bive of our 
six patients presented with early manilestations within the first year of life and 
a severe clinical course including lactic acidosis and neuromuscular symptoms. 
No patient shows an isolated myopathic disorder as reported in patients with 
isolated deficiemcies. A strong support for an additional effect on the clinical 
course from a combined PDHC/respiratory chain defect can be drawn from the 
observed intraiamiliar variability in the dizygotic twins (patients 6 and 7). In 
patient 6 with COX deficiency (16% residual activity of the mean of controls) 
and lowered PDHC activity, the illness was more severe than in his dizygotic 
twin brother with an isolated COX deficiency (COX activity 7% of the mean 
value of controls). Since the residual activity ot COX in the latter patient was 
lower than in his brother, it seems that at least in these twins the combination of 
defects had more severe effects than the residual activity of one affected enzy-
me In a study on patients with combined and isolated complex I deficiencies, 
more severe clinical findings were found in those with combined defects (6). 
In most cases with isolated PDHC deficiency no mitochondrial alterations 
can be detected under light and electron microscopy, whereas various structural 
mitochondrial abnormalities are usually found in disorders of the respiratory 
chain (12) Three of our 5 patients who were appropiately studied had mito-
chondrial alterations and in two the mitochondria were morphologically nor-
mal. 
On the basis of our investigations it is hard to explain the molecular mecha-
nism of combined deficiencies. The pyruvate dehydrogenase complex is situa-
ted in the matrix of the mitochondria and is probably only slightly associated 
with the inner mitochondrial membrane. While respiratory chain complexes are 
embedded in the inner membrane and are encoded both by mitochondrial and 
nuclear genomes (except for complex II), PDHC is encoded only by nuclear 
DNA The mechanism and regulation of the assembly of the subumts of the 
respiratory chain complexes is still obscure. In patients with combined deficien-
cies of respiratory chain enzyme complexes, both mitochondnally encoded and 
nuclearly encoded proteins can be lacking (17). The occurrence of deficiencies 
of both the pyruvate dehydrogenase complex and respiratory chain complexes 
might be due to a defective common mechanism for protein import and/or 
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assembly of PDHC and respiratory chain system Likely a disturbed protein 
import do not play a role in our patients, since we have found a normal immun­
ochemical signal of PDHC at least in 5 patients Another possibility is that a 
primary detect of the energy generating system induces, at least in some pati­
ents, a secondary defect at the transcriptional, translational or posttranslational 
level. 
The primary defect in patient 5 seems to be the PDHC deficiency which has 
also been found in cultured fibroblasts wheras reduction of cytochrome с oxida­
se activity is not present in fibroblasts But cytochrome с oxidase deficiency 
seems to be the primary defect in patient 6, as PDHC is normally active in his 
twin brother (patient 7). 
Surprisingly, in only one patient the defect could be observed in a cultured 
cell system, which suggests tissue specificity of the defects in most patients, as 
has been desenbed in cases with a defect in a single mitochondrial enzyme 
The observation of patients with combined PDHC and respiratory chain 
defects is important for several reasons First, the diagnostic procedure in mito­
chondrial myopathies should include measurement of all enzyme complexes of 
the mitochondrial energy generating system, including PDHC, to get a comple­
te insight into the route of pyruvate oxidation, even if a defect in the respiratory 
chain has already been established. Probably, combined deficiencies of PDHC 
and respiratory chain have not been found up to now, because several mito­
chondrial diagnostic laboratories have not examined both respiratory chain 
enzymes and pyruvate dehydrogenase complex. Enzyme measurement of 
PDHC is rather difficult (13) and is not carried out in many diagnostic centers. 
The PDHC measurement has been included in our diagnostic program during 
the last 5 years and we have found the presented combination of defects during 
the last 3 years with a frequency of about 5-10 % of the patients with an enzy­
matic defect in the mitochondrial energy production in muscle tissue. Secondly, 
the approach to therapy is different if PDHC is besides a respiratory chain 
defect involved (9) In patient 4, administration of thiamine and a ketogenic 
diet was followed by clinical improvement. Also patient 5 shows clinical 
improvement on therapy with cotactors stimulating PDHC Thirdly, an exact 
biochemical diagnosis has implications for prenatal diagnosis and genetic coun­
selling of these disorders Respiratory chain defects can be transmitted mater­
nally but a combination with a PDHC defect probably involves the nuclear 
genome and is related to Mendelian inheritance if the defect is primary. Finally 
the observation of combined PDHC and respiratory chain deficiency can stimu­
late basic research to elucidate more exactly the pathomechamsms of mitochon-
dnopathies 
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C H A P T E R 7 
SUMMARY AND CONCLUDING REMARKS 
a. Measurement of the activity of total activated pyruvate dehydrogen­
ase complex: 
Since PDHC can undergo an activation-mactivation cycle due to multisite 
phosphorylation and dephosphorylation, the conditions for PDHC measurement 
in vitro have to be well defined. Enzyme measurements are preferentially car­
ried out in muscle tissue. It has been shown that a PDHC defect is not always 
expressed in fibroblasts (8). Totally activated PDHC is considered to reflect the 
activity of the completely dcphosphorylated enzyme complex. The basal activi­
ty probably reflects the phosphorylation status in vivo, a condition which is 
hardly reproducible in vitro. Even after application of freeze clamping and inhi­
bition of the regulation system of PDHC, the phosphorylation status of the 
enzyme complex remains unclear. In diagnosing mitochondrial myopathies, the 
accurate measurement of a well-defined basal PDHC activity seems impossible. 
Therefore investigations have been carried out to set up a method tor measure­
ment of a completely stimulated PDHC m muscle tissue (see Chapter 2). 
Furthermore, total PDHC activity measured in 600 g muscle supernatant corre­
lates well with pyruvate oxidation rate in the same supernatant. The pyruvate 
oxidation rate is measured under circumstances comparable with state 3 condi­
tions of oxidative phosphorylation in isolated mitochondria. 
b. Age dependency of the enzyme activity: 
Knowledge of the age dependency of mitochondrial enzymes and especially 
of the key enzyme PDHC is of utmost importance for the diagnosis of mito­
chondrial myopathies. PDHC deficiency can cause severe congenital lactic aci­
dosis already in the neonatal period. Diagnosis of mitochondrial defects in this 
period of lite is dependent on the knowledge of age related features of the mito­
chondrial energy producing system In Chapter 3 the results of studies in 
muscle tissue of the newborn rat and human neonates are presented. In the ani­
mal study (Chapter З.1.), pyruvate oxidation and PDHC activity are signifi­
cantly lower in newborn than in adult rats. There is an increase of the enzyme 
activity up to the weaning period. Interestingly, the protein concentration of the 
regulatory subunit of PDHC, Eia, increases most rapidly with age. Possibly 
Ε,α mRNA is translated to an increasing extent during development, a mecha­
nism observed for respiratory chain proteins (1) 
In human neonates (Chapter 3.2.), lower PDHC values were found in pre­
mature babies than in older children and adult controls, whereas babies bom at 
term already show an enzyme activity in the range of older children and adult 
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controls. Other enzymes involved in oxidative phosphorylation and substrate 
oxidation rates were lower in term bom babies than in the controls. The durati­
on of pregnancy and age of the patient must therefore be taken into account 
when interpreting PDHC activities in newborns. 
с Immunochemical detection of PDHC subunits: 
Enzyme measurement is an important step in the diagnosis of PDHC defi­
ciencies, but further evaluation is possible using immunochemical detection of 
the individual subunits. Chapter 4 presents a patient with a PDHC defect, for 
whom immunochemical analysis of the multienzyme complex was performed. 
High residual activities of PDHC in patients with a suspected mitochondrial 
disease are difficult to interprete. Furthermore, enzyme activity of PDHC in 
fibroblasts does not accurately reflect the status in other tissues. 
Immunochemical analysis of PDHC provides additional, more detailed infor­
mation on the subunit pattern of the multienzyme complex in the diagnostic 
procedure. 
d. Tissue specificity of mitochondrial defects: 
Although it has not yet been possible to delect isoenzymes of PDHC (3,7), 
some differences in tissue expression of defects were demonstrated in a survey 
of patients with mitochondrial myopathies (Chapter 5).It ispossible that there 
are multiple gene copies for specific E, subunits, which are differentially 
expressed in various tissues and are separately affected by mutations (6,12). 
Tissue specificity is very important for the diagnosis of mitochondrial myopa­
thies, and it has been shown that PDHC deficiency is not expressed in cultured 
fibroblasts in several patients. Skeletal muscle is the tissue of choice in the dia­
gnosis of mitochondrial (encephalo-)myopathies. 
e. Combined deficiencies of PDHC and respiratory chain complexes: 
Patients with combined deficiencies of PDHC and the respiratory chain, pre­
sented in Chapter 6, have been reported for the first time. Only very recently, a 
second report on fatal combined defects in two siblings has been published 
( 12). The diagnostic procedure in mitochondrial myopathies should not be con­
sidered complete after the finding of one enzyme deficiency affecting the mito­
chondrial energy generating system. The therapeutic approach is different if 
PDHC is deficient inaddition to a respiratory chain defect. Furthermore, exact 
biochemical diagnosis has implications for prenatal diagnosis and genetic coun­
selling of these disorders. Respiratory chain defects can be transmitted mater­
nally, but a combination with a PDHC defect probably involves the nuclear 
genome and is related to Mendelian inheritance if the PDHC defect is primary. 
The observation of combined PDHC and respiratory chain deficiency will sti-
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muíate basic research to elucidate more exactly the pathogenetic mechanisms 
of mitochondriopathies. 
f. Genetica! and therapeutic considerations: 
The detection of the gene locus for E ^ and Eiß has extended the diagnostic 
possibilities in PDHC deficiency to the DNA level. The localisation of Ε,α on 
the X chromosome has given new insights and explanations for the clinical pre­
sentation of most cases of PDHC deficiencies. Besides X-linked forms of the 
disease, where the defect involves the Ε,α subunit, autosomal recessively inhe­
rited forms occur if other subunits are affected. Especially in females with E ^ 
deficiency, the severity of the disease is dependent on the X chromosome inac-
tivation pattern (9). 
Since PDHC catalyzes a multistep reaction involving five different cofac-
lors, thiamine pyrophosphate (TPP), dihydrolipoamide [LipCSHb), nicotinami­
de adenine dinucleotide (NAD), flavin adenine dinucleotide (FAD), and CoA, 
several trials for therapy can be carried out in PDHC deficiency. 
Administration of thiamine, riboflavin and lipoic acid has been reported to have 
variable success (4,10,11 ).Therapy with dichloroacetate, an inhibitor of PDH 
kinase, has been shown to be effective in lowering lactate levels in serum (2,5), 
but long term use can lead to neurotoxicity (13). A ketogenic diet with some 
beneficial effect in a patient with Leigh's disease and PDHC deficiency has 
been described (14). Nevertheless, so far no effective treatment is available for 
most cases of PDHC deficiency or other defects of the mitochondrial energy 
producing system. Therefore, genetic counselling of the affected families after 
early and accurate detection of PDHC defects is very important. 
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SAMENVATTING 
a. Meting van de activiteit van het totaal geactiveerde pyruvaat dehy-
drogenase complex: 
Aangezien het pyruvaat dehydrogenase complex vanwege multipele (de-) 
fosforylenng een activermgs-inactiverings-cyclus ondergaat, 7ijn gedefinieerde 
omstandigheden voor de PDHC bepaling m vitro noodzakelijk. Bepaling van 
totaal geactiveerd PDHC in spierweelsel impliceert meting van de activiteit van 
het volledig gedefosfory leerde enzymcomplex. De basale activiteit is moeilijker 
te definieren. Waarschi)nli|k geeft de/e basale activiteit de fosforylenngstoe-
stand in vivo weer, een omstandigheid die in vitro met reproduceerbaar is De 
stabiliteit van de fosforylenngstoestand van het enzymcomplex blijft onduideli-
jk, zelfs met methoden zoals "freeze-clamping" en na remming van het regula-
tiesysteem van PDHC In de diagnostiek van milochondnele myopathieen lijkt 
een betrouwbare meting van de basale PDHC activiteit onmogeli|k. 
Daarom is er onderzoek uitgevoerd om een methode te ontwikkelen voor de 
meting van het volledig gestimuleerde PDHC in spierweefsel (Hoofdstuk 2). 
Er bestaat een nauwe correlatie tussen pyruvaatoxidatiesnelheden en PDHC 
activiteit in vitro, beide gemeten onder maximaal gestimuleerde omstandighe-
den in 600 g spiersupernatant. 
b. Leeftijdsafhankelijkheid van de enzymcomplex activiteit: 
Kennis van de leeftijdsafhankelijkheid van de activiteit van de mitochon-
dnele en/ymen en met name van het sleutelen/ym PDHC, is van allergrootste 
belang voor de diagnostiek van milochondnele myopathieen. PDHC deficiëntie 
kan zich in de neonatale periode al uiten in de vorm van een ernstige congenita-
le lactaatacidose Betrouwbaarheid van de diagnostiek van mitochondnelc 
defecten in de/e levensfase is sterk afhankelijk van de kennis van de leeftijdsaf-
hankelijke ontwikkeling van enzymen betrokken bij het mitochondnelc ener-
gie-producerende systeem Hoofdstuk 3 geeli de resultaten weer van studies in 
spierweelsel van pasgeboren rat en van humane neonaten. In de proefdierstudie 
(Hoofdstuk 3.1) zijn pyruvaatoxidatie-snelheid en PDHC activiteit significant 
lager in neonaten dan in volwassen controledieren Er bestaat een toename van 
de en/ymactiviteit lot aan de periode van het spenen. 
Bij humane neonaten (Hoofdstuk 3.2) werden lagere PDHC waarden gevon-
den bij prematuren, in vergelijking met oudere kinderen of volwassen contro-
les à Terme geboren babies vertonen een PDHC activiteit vergelijkbaar met die 
van oudere kinderen of volwassen controles. Andere mitochondnelc en/ymac-
tiviteiten en substraatoxidatie-snelheden waren lager bij à terme geboren babies 
dan bij de controles Kennis van deze leeftijdsafhankelijkheid van de biochemi-
sche parameters is uitermate belangrijk voor de interpretatie van PDHC activi-
teiten in de neonatale periode. 
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с. Immunochemische detectie van PDHC subunits: 
Enzyrructiviteitsmeting vormt slechts een onderdeel in de diagnostiek van 
PDHC deficiënties. Nadere evaluatie kan plaatsvinden met behulp van immun-
ochemische technieken. In Hoofdstuk 4 wordt de immunochemische analyse 
van het PDHC complex van een patient m et een PDHC deficiëntie beschreven. 
Hoge Testactiviteiten van PDHC bij patiënten met een verdenking op een mito-
chondnele ziekte zijn moeilijk te interpreteren. Immunochemische analyse van 
PDHC levert verdere informatie over het subumtpatroon van het multienzym-
complex bij de diagnostische procedure. 
d. Weefselspecifiteit van mitochondriele defecten: 
Alhoewel tot nu toe geen isoen/ymen van PDHC beschreven zijn, konden 
toch verschillende weefselspecifieke expressies van defecten worden aangeto-
ond bij patiënten met mitochondriele myopathieen. Mogelijk bestaan er multi-
pele gen copieen voor specifieke Ej subunits die verschillend tot expressie 
komen in verscheidene weefsels, en afzonderlijk zijn aangedaan door mutaties 
(Hoofdstuk 5). Weefselspecificiteit is zeer belangrijk in het kader van de dia-
gnostiek van mitochondriele myopathieen. Het is bekend dat PDHC deficiëntie 
met altijd tot expressie komt in gekweekte fibroblasten. De diagnostiek van 
mitochondriele encephalomyopathieen wordt bij voorkeur in skeletspier ver-
richt. 
e. Gecombineerde deficiëntie van PDHC en ademhalingsketencomple-
xen: 
Patienten met gecombineerde deficiënties van PDHC en ademhalingsketen-
complexen, zoals in Hoofdstuk 6 gepresenteerd, zijn tot nu toe nog niet 
beschreven. De diagnostische procedure bij mitochondriale myopathieen dient 
meting van alle enzymcomplexen van het mitochondriele energiegenererende 
systeem te omvatten, dus inclusief PDHC. Op die wijze verkrijgt men volledig 
inzicht in het verloop van de pyruvaatoxidatie. Zelfs indien reeds een defect in 
de ademhahngsketen is aangetoond , dient de activiteit van PDHC alsnog 
gemeten te worden. De therapeutische benadering is verschillend indien er een 
defect in PDHC naast een defect in de ademhahngsketen aanwe7ig is. 
Bovendien is een exacte biochemische diagnose vereist voor adequate prenatale 
diagnostiek en genetische advisering van deze afwijkingen. 
Ademhahngsketendefecten kunnen maternaal overdragen worden, maar bij 
een combinatiemet een PDHC defect is waarschijnlijk het nucleair genoom 
betrokken. 
Bij een primair defect in PDHC is er sprake van mendehaanse overerving. 
De waarneming van gecombineerde PDHC- en ademhalmgsketendeficienties 
zal het basale onderzoek stimuleren teneinde de pathogenetische mechanismen 
van mitochondriopathieen op te helderen. 
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ZUSAMMENFASSUNG 
a. Bestimmung der Enzymaktiviat des total aktivierten Pyruvatdehy-
drogenasekomplexes: 
Da die Regulierung von PDHC einem Aktivierungs-Inaktivierungszyklus 
durch Phosphorylicrung/Dephosphorylierung unterliegt, sind genau definierte 
Bedingungen fur die in vitro Enzymaktivitatsbestimmungen von PDHC not-
wendig. Die total aktivierte PDHC Aktivität wird bei vollständiger 
Dephosphorylierung des En/ymkomplexes gemessen. Die basale Aktivität ist 
hingegen viel schwieriger zu definieren Es sollte eigentlich eine sogenannte 
"basale Enzymaktivitat" den Phosphorylierungsgrad des Multienzymkomplexes 
in vivo wiederspiegeln, ein Zustand, der unmöglich unter in vitro Bedingungen 
erfaßt werden kann Auch mit Methoden wie Freeze-Clampmg und 
anschließender Hemmung des Regulationssystem von PDHC bleibt unklar, ob 
ein stabiler Phosphorylierungsgrad des Enzyms fur in vitro Messungen erhalten 
werden kann Fur die Diagnostik von mitochondrialen Myopathien scheint eine 
profunde Bestimmung einer basalen PDHC Aktivität unmöglich zu sein. Mit 
unserem Enzymassay wollten wir eine Methode zur Bestimmung einer maxi-
mal aktivierten PDHC Aktivität entwickeln (Kapitel 2). Diese maximal stimu-
lierte PDHC Aktivität wurde mit Pyruvatoxidationsraten im selben 600 g 
Muskelsupematant verglichen Dabei ergab sich eine enge Korrelation zwi-
schen dem Umsatz von Pyruvat durch PDHC und den Pyruvatoxidationsraten 
in intakten Mitochondnen Unter State 3 Bedingungen scheint PDHC "Rate 
limiting" fur die Pyruvatoxidation in intakten Mitochondnen zu sein. 
b. Altersabhangigkeit der Enzymkomplexaktiv ¡tat: 
Die Kenntnis der Altersabhangigkeit mitochondrialer Enzyme und besonders 
der des Schlusselenzymes PDHC ist von großer Bedeutung in der Diagnostik 
mitochondrialer Myopathien PDHC Defekte können bereits in der 
Neugeborenenpenode unter dem Bild einer schweren kongenitalen 
Laktatazidose beobachtet werden. Die Diagnostik von mitochondrialen 
Defekten in dieser Lebensperiode verlangt eine besondere Kenntnis altersspezi-
fischer Veränderungen des mitochondrialen Oxidationsapparates In Kapitel 3 
werden Ergebnisse von Studien in neonatalem Muskelgewebe presentiert. Beim 
Tiermodell (Kapitel 3.1) findet sich eine signifikant niedrigere 
Pyruvatoxidation und PDHC Aktivität bei neugeborenen im Vergleich zu 
erwachsenen Tieren. Es kommt zu einem Anstieg der Enzymaktivitat besonders 
bis hin zur Abstillpenode. 
Beim humanen Neugeborenen (Kapitel 3.2) finden sich niedrigere PDHC 
Aktivitäten bei frühgeborenen Kindern verglichen mit alteren Kindern oder 
erwachsenen Kontrollpatienten Termmgeborene hingegen weisen bereits eine 
relative hohe Enzymaktivitat auf, welche im Bereich von alteren Kindern oder 
Erwachsenen liegt. Andere mitochondriale Enzymaktivitaten und 
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Substratoxidationsraten waren bei den tenmmgeborenen Kindern niedriger als 
bei den alteren Kontrollen Fur die Interpretation von mitochondrialen 
Enzymaktivitaten in der Neugeborenenpenode sind somit Gestations-und 
Lebensalter zu berücksichtigen 
с Immunochemische Darstellung der PDHC-Untereinheiten: 
Enzymaktivitatsmessungen sind ein wichtiger Schritt in der Diagnostik von 
PDHC Defizienzen Eine weitere Charakterisierung ist mit immunochemischer 
Darstellung der einzelnen Untereinheiten von PDHC möglich In Kapitel 4 
wird die Abklärung eines Patienten mit PDHC Defi/ienz mittels immunoche-
mischer Methoden dargestellt Hohe Residualaktivitaten von PDHC bei 
Patienten mit Verdacht auf mitochondriale Myopathie sind schwieng zu inter-
pretieren. Die PDHC Aktivität in Fibroblasten reflektiert in der Regel nicht die 
Enzymaktivitaten in anderen Geweben Eine immunochemische Analyse von 
PDHC bietet fur den Diagnoseablaut bei Mitochondnopathien wichtige weitere 
Informationen bezüglich des Untereinheitenmusters des Multienzymkom-
plexes. 
d. (¡ewebespezifitat mitochondrialer Defekte: 
Obwohl bisher keine Isoenzyme von PDHC beschrieben wurden, wurde 
doch eine unterschiedliche Expression von PDHC-Defekten in verschiedenen 
Geweben im Rahmen einer Übersicht von Patienten mit mitochondnaler 
Myopathie gezeigt (Kapitel 5). Möglicherweise existieren multiple Genkopien 
fur spezielle E| Untereinheiten, welche unterschiedlich in den ein/einen 
Geweben cxpnmiert werden und separat von Mutationen betroffen sein kön-
nen Die Gewebespe/ifitat mitochondrialer Enzyme muß unbedingt bei der 
Diagnostik mitochondrialer Myopathien berücksichtigt werden. PDHC Defekte 
kommen nicht immer in kultivierten Hautfibroblasten zur Expression. Der Wert 
von Fibroblastenkulturcn bei der Diagnostik dieser Krankheitsgruppe scheint 
dadurch limitiert Skelettmuskulatur ist nach wie vor das Gewebe der ersten 
Wahl bei der Abklärung mitochondrialer Enzephalomyopathien. 
e. Kombinierte PDHC/Atmungskettenkomplexdefizienz: 
Patienten mit kombinierten Defekten von PDHC und Atmungsketten-
enzymen wurden zum ersten Mal in der Literatur berichtet (Kapitel 6) Das 
diagnostische Vorgehen bei mitochondrialen Myopathien sollte nicht abge-
schlossen sein, wenn bereits ein Defekt im Bereich der oxidaliven 
Phosphorylierung gefunden wurde. Der therapeutische Ansatz ist namheh 
unterschiedlich, wenn neben einem Atmungskettendefekt auch noch PDHC 
defizient ist. Weitcrs hat eine exakte biochemische Diagnose Konsequenzen fur 
die prenatale Diagnose und die genetische Beratung dieser Patienten. 
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Atmungskettendefekte können matemal vererbt werden, eine Kombination mit 
einem PDHC Defekt involviert das nukleare Genom und unterliegt der 
Mendelschen Vererbung. Die Beobachtung von kombinierten PDHC- und 
Atmungskettendefekten ist eine Herausforderung für die Grundlagenforschung, 
weitere Pathomechanismen mitochondrialer Erkrankungen zu studieren. 
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STELLINGEN 
ι 
Determination of the activity of the pyruvate dehydrogenase complex only in 
fibroblasts is inadequate in the majority of patients suffering from such an 
enzyme deficiency. (This thesis) 
II 
Age related reference values are necessary for a correct interpretation of bio­
chemical results in case of mitochondrial encephalomyopathies in the neonatal 
period. (This thesis) 
III 
The diagnostic procedure in mitochondrial myopathies should include measure­
ment of all enzyme complexes of the mitochondrial energy generating system, 
including the pyruvate dehydrogenase complex, to obtain a complete insight 
into the route of pyruvate oxidation, even if a defect in the respiratory chain has 
already been established. (This thesis) 
IV 
Reconstructions of the family tree of homo sapiens by phylogenetic analysis of 
extant mitochondrial DNA have not been able to prove that the human race had 
its origins in Africa but there is no doubt, that all human races descended from 
a common female ancestor. (H. Gee, Nature 1992, 355: 583) 
V 
The fact, that the capacity of the mitochondrial energy producing processes 
declines with increasing age, is one major explanation why lifespan is limited. 
(D.C. Wallace, Science 1992, 256: 628-32) 
VI 
Since the first publication in the Netherlands, that prone position has something 
to do with increased incidence of SIDS, several studies in three races, four con-
tinents and seven countries have proven that the increased risk for SIDS is asso-
ciated with the prone sleeping position. (W.G. Guntheroth, P.S. Spiers, JAMA 1992,267: 
2359-62) 
VII 
It is illogical to call the river Rijn the Waal after it branches at Pannerden. 
Vili 
People who enjoy deep-snow skiing should be aware that there is an acute dan-
ger of avalanches if more than 50 cm of new snow fall within 24 hours. 
IX 
By marrying an Italian wife from South Tyrol, the author instinctively followed 
the most successful Austrian approach to politics: " Tu felix Austria, nube ! " 
Nijmegen, 13. 10. 1992 Wolfgang Speri 


